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RIASSUNTO
La  citofluorimetria  è  una tecnica in  continuo sviluppo e,  ad  oggi,  ricopre un  ruolo  
fondamentale  nella  diagnosi  e  nella  classificazione  dei  tumori  ematopoietici  in 
medicina umana.
Diversi studi affermano che le informazioni ottenute dall'analisi citofluorimetrica, oltre 
a  definire  l'immunofenotipo delle  cellule  tumorale,  quindi  l'origine  della  neoplasia,  
possono aiutare a  prevederne il comportamento biologico.
Questa tecnica è così diventata un metodo semplice e oggettivo per caratterizzare i 
tumori ematopoietici, dalla quale ottenere anche preziose informazioni prognostiche 
(Swerdlow et al., 2016). 
In medicina veterinaria, la citofluorimetria è sempre più utilizzata per la diagnosi, la 
stadiazione ed il  monitoraggio dei  tumori  ematopoietici,  ma nonostante i  progressi 
nella  generazione  e  nella  validazione  di  anticorpi  per  l'utilizzo  nel  cane,  la 
caratterizzazione di tali neoplasie rimane una sfida, soprattutto per alcuni sottotipi di 
neoplasie meno conosciuti (Wilkerson et al., 2005; Comazzi and Gelain, 2011). 
L'obiettivo  di  questo  progetto  di  dottorato  è  di  descrivere  alcuni  sottotipi  meno 
frequenti di  linfomi e leucemie del cane tramite l'applicazione della citofluorimetria, di  
definirne il comportamento biologico e di indagare se vi siano delle variabili di valore 
prognostico tra tutti i fattori analizzati. 
A questo scopo, verranno illustrati quattro studi; il primo, è un lavoro retrospettivo che 
ha la finalità di valutare fattori preanalitici che possono influire sull'utilità diagnostica 
della citofluorimetria in campioni di aspirato linfonodale. Nel lavoro sono stati inclusi 
987  casi  selezionati  nel  periodo  2009-2015,  giunti  con  sospetto  di  patologia 
linfoproliferativa e con presenza di un campione di aspirato linfonodale. Le variabili 
analizzate  sono  relative  all'animale  (razza,  sesso,  età),  relative  all'operatore  (anno, 
stagione,  metodo  di  spedizione  al  laboratorio,  veterinario  referente)  e  relative  al 
campione (tipo di  materiale,  concentrazione cellulare,  presenza di  vetrini  citologici, 
presenza di artefatti). Dei fattori considerati, la cellularità del campione e la presenza 
di  cellule  morte  sono  quelli  che  hanno  maggiormente  influenzato  la  possibilità  di 
ottenere una diagnosi. La citofluorimetria è comunque risultata conclusiva nella quasi 
totalità  dei  campioni,  caratterizzati  da  buona  qualità  ed  adeguate  condizioni  di 
campionamento. 
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Il  secondo studio,  focalizzato  sul  T-zone lymphoma (TZL),  un sottotipo peculiare di  
linfoma canino con caratteristico comportamento indolente, ha come scopo quello di 
caratterizzare questa entità tumorale dal punto di vista clinico e patologico. La prima 
fase del lavoro è di tipo retrospettivo, col  fine di descrivere presentazione clinica e 
outcome di 51 casi selezionati tra il 2009 e il 2014. La seconda fase dello studio ha lo 
scopo di chiarire l'origine del peculiare immunofenotipo T CD45 negativo  (Martini et 
al.,  2013;  Seelig  et  al.,  2014);  nello  specifico,  è  stata  confermata  l'assenza  della 
proteina  di  superficie  tramite  due  diverse  tecniche  (citofluorimetria  ed 
immunoistochimica)  ed  è  stato  valutato  se  fossero  presenti  il  trascritto  e  il  gene 
codificante  la  proteina.  Dai  risultati  è  emerso  che  questo  tipo  di  linfoma  ha 
comportamento indolente e con lunghi tempi di sopravvivenza, nonostante sia spesso 
diagnosticato  al  V  stadio  della  patologia.  Inoltre,  è  stato  constatato  che  l'origine 
dell'aberranza  fenotipica  è  probabilmente  attribuibile  a  fattori  trascrizionali,  vista 
l'assenza di trascritto e la presenza del corrispondente tratto genomico.
Il terzo studio ha invece come scopo la descrizione del comportamento biologico del 
linfoma marginale  di  tipo  nodale  (nMZL).  Nonostante  in  letteratura  sia  classificato 
come linfoma indolente, alcune pubblicazioni riportano casi con un comportamento 
piuttosto aggressivo  (Flood-Knapik et al., 2012; Valli et al.,  2013; Aresu et al.,  2015; 
Marconato et al., 2015). Sono state raccolte informazioni cliniche di 35 casi di nMZL 
retrospettivamente selezionati, con stadiazione completa e terapie standardizzate. E' 
così emerso che nella nostra casista questo linfoma aveva comportamento tutt'altro 
che  indolente,  con  un  coinvolgimento  generalizzato  e  con  tempi  di  sopravvivenza 
brevi,  quasi  sovrapponibile  al  linfoma diffuso  B  a  grandi  cellule  (DLBCL).  Grazie  ai  
risultati  di  questo lavoro,  si  potrebbero aprire discussioni  sull'approccio terapeutico 
più corretto.
L'ultimo studio ha invece lo scopo di  proporre  nuovi  anticorpi  per la  diagnosi  e  la 
stratificazione dei pazienti affetti da leucemia linfocitica cronica a cellule B (CLL-B), un 
sottotipo di leucemia meno frequente nel cane ma dall’elevato interesse comparativo.  
L'espressione dei markers ZAP70 e CD38 in medicina umana è strettamente relazionata 
all'andamento  della  malattia,  con  sopravvivenze  molto  inferiori  nei  pazienti  con 
espressione  oltre  certe  soglie  (Rossi  et  al.,  2010;  Sulda  et  al.,  2012).  Nel  presente 
progetto, questi markers sono stati valutati per la prima volta in citofluorimetria su 37 
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casi di leucemia cronica B di cane, insieme a CD25 e ki67. Sono state raccolti i follow-
up dei casi selezionati e l'analisi della sopravvivenza ha infine rivelato che ZAP70 è un 
potenziale  marker  di  prognosi,  fornendo  basi  per  ulteriori  studi  prognostici,  con 
casistica più ampia e terapia standardizzate.
I  risultati  del  mio  progetto  di  dottorato  confermano  che  la  citofluorimetria  è  una 
buona tecnica per  la diagnosi  e  lo studio degli  aspetti  clinico-patologici  dei  tumori 
linfoproliferativi  del  cane.  Inoltre,  la  descrizione  di  questi  tumori  ha  fornito 
informazioni utili a completarne il profilo biologico, gettando anche le basi per futuri 
approfondimenti in merito ai risultati ottenuti.
ABSTRACT
Flow cytometry (FC) is a diagnostic technique in continuous development and, to date, 
it plays a fundamental role in human medicine for the diagnosis and the classification 
of hematopoietic tumors.
Several studies state that the information obtained from the FC analysis in addition to 
defining the immunophenotype of the tumor cells, hence the origin of the neoplasia, 
can help to predict its biological behavior (Swerdlow et al., 2016).
FC has  thus  become a simple and objective method to characterize  hematopoietic 
tumors in order to obtain also valuable prognostic information.
In  veterinary  medicine,  FC  is  increasingly  adopted  for  the  diagnosis,  staging,  and 
monitoring  of  hematopoietic  tumors,  but  despite  advances  in  the  generation  and 
validation of antibodies for the use in dogs, the characterization of such neoplasms 
remains challenging (Wilkerson et al., 2005; Comazzi and Gelain, 2011). 
The  aim  of  this  doctoral  project  is  to  describe  some  less  frequent  subtypes  of 
lymphomas and leukemia of the dog via FC, in order to define its biological behavior 
and to investigate  whether there is any variable of prognostic  value among all  the 
factors analyzed.
For  this  purpose,  four  studies  will  be  illustrated;  the  first is  a  retrospective  work, 
aiming to evaluate pre-analytical factors that may affect the diagnostic utility of FC in 
samples of lymph node aspirates. The work included 987 cases selected in the period  
2009-2015, in which a lymph node aspirate was sent to our laboratory with suspect of 
lymphoproliferative disease. In order to define any possible bias affecting the outcome 
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of the FC diagnosis, the variables analyzed were related to the animal (breed, sex, age), 
related to the operator (year, season, method of delivery to the laboratory, referring 
veterinarian) and related to the sample (type of material, cell concentration, presence 
of  cytological  slides,  presence  of  artifacts).  Of  the  factors  considered,  the  sample 
cellularity  and the presence of  dead cells  were the ones that  most  influenced the 
possibility of obtaining an adequate diagnosis. FC was, however, conclusive in almost 
all  the  samples,  that  were  characterized  by  good  quality  and  adequate  sampling 
conditions.
The study focused on TZL,  a  peculiar  canine lymphoma with an indolent behavior, 
aimed to characterize this entity from a clinical and pathological point of view. The first 
phase of the work was retrospective, with the aim of describing clinical presentation 
and outcome of 51 cases selected between 2009 and 2014. The second phase of the 
study  was  aimed  at  clarifying  the  origin  of  the  peculiar  CD45  negative  T-
immunophenotype (Martini et al., 2013; Seelig et al., 2014); specifically, we confirmed 
the  absence  of  the  surface  protein  by  means  of  two  different  techniques  (flow 
cytometry and immunohistochemistry)  and verified whether the transcript  and the 
gene  encoding  the  protein  were  present.  The  results  confirmed  that  this  type  of 
lymphoma  has  indolent  behavior  with  long  survival  times,  despite  being  often 
diagnosed at the V stage of the disease. Furthermore, we can note that the origin of 
the phenotypic aberration is probably attributable to transcription factors, given the 
absence of transcription associated with the presence of the corresponding genomic 
tract.
The  objective  of  the  third  study  was  focused  on  the  description  of  the  biological 
behavior  of  nodal-type  marginal  lymphoma  (nMZL).  Although  in  literature  it  is 
classified  as  indolent  lymphoma,  some  publications  reported  cases  with  a  rather 
aggressive behavior (Flood-Knapik et al.,  2012; Valli  et al.,  2013; Aresu et al.,  2015;  
Marconato  et  al.,  2015).  Clinical  information was collected from 35 retrospectively 
selected nMZL cases, with complete staging and standardized therapies. In our cohort, 
this lymphoma did not show and indolent  behavior, with a generalized involvement 
and with short survival  times, almost overlapping with the high-grade diffuse B-cell 
lymphoma (DLBCL). Thanks to the results of this work, discussions could be opened on 
the correct therapeutic approach.
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The latest study aimed to evaluate new antigens for the diagnosis and stratification of 
patients  with  CLL-B.  The  expression  of  the  ZAP70  and  CD38  markers  in  human 
medicine is closely related to the progression of the disease, with much lower survivals  
in patients with expression over specific thresholds  (Rossi et al.,  2010; Sulda et al., 
2012). In the present project, these markers were evaluated for the first time in 37 
blood samples of  dogs with chronic  B-cell  leukemia,  together  with CD25 and ki67. 
Clinical  data  of  the cases  were obtained and survival  analysis  finally  revealed that  
ZAP70 is a potential prognostic marker, providing bases for further studies with larger 
case studies and standardized therapy.
The results of my doctoral project confirm that FC is a good technique for the study of 
the clinical-pathological aspects of lymphoproliferative tumors of dogs, and provides 
useful information to complete the biological profile of these tumors, also laying the 
foundations for future investigations on the usefulness of the proposed new markers.
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1. Introduction
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When  a  canine patient  presents  with  lymphadenopathy,  the  list  of  differential 
diagnosis  suggested  by  clinicians  and  clinical  pathologists  generally  includes 
lymphoproliferative disorders.  Lymphoproliferative disorders  often  present  with  a 
diagnostic dilemma: is this a neoplastic process?
Immunophenotyping by Flow Cytometry (FC), to date, represents an important step 
for distinguishing the origin of cells, thus helping in differentiating non-neoplastic from 
neoplastic cells. 
Over  the last  decade,  FC evolved from a promising  new technology  to an  integral  
component of research in the life sciences, particularly immunology, and a common 
element of diagnostic and prognostic investigations in human oncology, specifically, 
hemato-oncology  (Craig  and  Foon  2008;  Wood  et  al.,  2008;  Stewart  and  Stewart, 
2011).  
In  Veterinary  Medicine,  FC  is  a  service  provided  by  an  increasing  number  of 
laboratories,  most  of  which  are  in  veterinary  schools.  In  veterinary  research, 
measurement of cell fluorescence may be employed for immunophenotyping, ploidy 
analysis, functional cell assays, or determination of transfection efficiency with genes 
encoding fluorescent proteins. However, one of the most important applications is the 
diagnosis, classification, staging, and monitoring of hematologic neoplasms  (Comazzi 
and Gelain 2011; Wilkerson 2012; Comazzi et al., 2017, Marconato et al., 2013; Aresu 
et al., 2014; Riondato et al., 2017).
In both humans and canines, lymphomas and leukemias demonstrate heterogeneity in 
regards  to  presentation,  behavior,  genetic  characteristics,  and  patient  outcome, 
offering  a  multitude  of  challenges  to  better  characterize  the  disease  (Valli  and 
MacEwen, 2010; Khanna et al. 2006; Marconato et al., 2013, Richards and Suter, 2015). 
Indeed, the area of major promise is the identification of molecular markers, that may 
predict the response to therapy and tumor relapse, thereby offering clinically useful 
information.
Over the last years, several researchers have attempted to stratify canine patients into 
prognostic groups within the application of different techniques. It is known that many 
flow cytometric features, such as cell size and expression of specific antigens, can be 
important prognostic factors for certain types of lymphoproliferative tumors (Comazzi 
et al., 2011; Seelig et al., 2014). Richards et al. (2015) used immunohistochemistry and  
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the gene expression profile (GEP) on canine DLBCLs for the identification of germinal 
center and post-germinal  center subtypes, including different survival times, partially 
reflecting human DLBCL. Another group used GEP on 35 canine lymphoma samples to 
define three major genomic groups: (i) low-grade T-cell lymphoma, (ii) high-grade T-
cell  lymphoma and (iii) B-cell lymphoma, associated with different clinical outcomes 
(Frantz et al., 2012). 
        Also the DNA methilome of canine DLBCLS has been investigated by genome-wide CpG 
microarray, revealing a common signatures of tumorigenesis and defined epigenetic 
prognostic subtypes (Ferraresso et al., 2017).
Again, IGHV mutational status, which is the major prognostic factor in human CLL, has 
been recently  explored in  canine CLL  by  sequencing  the IGHV-D-J  rearrangements, 
disclosing that Boxer breed has prevalently an unmutated IGVH status, thus opening 
for further detailed studies (Rout et al., 2018).
A number of different methods can be used for the characterization of hematopoietic 
tumors,  however, molecular  biology  techniques  are  still  not  sensitive  and  specific 
enough to be regarded as a reliable tool for final diagnosis. 
In spite of the different  techniques available, FC remains a cost-effective, minimally 
invasive, sensitive and rapid tool to generate results from a cell population. It gives the 
opportuniti  to  obtain a  better  range  of  information,  thanks  to  the examination  of 
multiple parameters,  including cell  surface proteins, intracellular  proteins, size,  and 
complexity  of  individual  cells  (Nguyen  2007).  The  main  edge  of  FC  is  that  the 
expression  of  several  antigens  can  be  assessed  simultaneously  on  any  given  cell 
population,  in  contrast  with  the  limited  number  of  markers  that  can  be  used  in 
immunostaining on tissue sections or cytological smears. 
The availability of a wide range of specific antibodies and different fluorochromes have 
improved the ability of  FC to characterize cell lineages and  to recognize phenotypic 
aberrancies in many neoplasms.  Consequently, FC has acquired a prominent position 
in  the  current  World  Health  Organization  (WHO)  classification  of  hematological 
malignancies in humans. The final goal of the human's WHO classification is helping to 
identify homogeneous groups of well-define entities and to facilitate the oncologist to 
include the patient in specific risk groups. In dogs WHO classification is currently based 
on the principles initially defined in the Revised European-American Classification of 
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Lymphoid  Neoplasms  (REAL)  (Harris  et  al.,  2004), endorsing  a  multiparametric 
approach to diagnosis  and outlines the morphologic,  immunophenotypic,  molecular 
and clinical features characteristic of each disease entity; it is not static and continues 
to be refined (Swerdlow et al., 2016). 
The past decade has also seen refinement of the criteria for classification and grading 
of canine lymphoma,  with widespread adoption of the human's WHO classification: 
the classification tend to reflect the analogous in people, grouping entities by cytology, 
histology,  and immunophenotype, while clinical, pathological, and genetic/molecular 
data are not yet well established (Valli et al., 2011). However, the range of monoclonal 
antibodies for a veterinary use is still restricted to allow standardization of panels for 
specific diseases subtypes (Williams et al.,  2008). Thus, the characterization of tumor 
entities according to phenotypic markers is still a challenge.
Nevertheless, canine tumors represent valuable tools for studying interesting aspects 
of human cancer: the canine model has some advantageous characteristics compared 
to  mice,  since  neoplasia  arises  and  grows  in  immune-competent  animals,  thus 
behaving similarly to what happens in affected humans. In addition, privately owned 
dogs share the same environment of humans and are exposed to the same risk factors 
that  contribute  to  the  development  of  many  neoplasms,  including  lymphoma  and 
leukemia. Careful attention to anatomic, morphologic, molecular, and clinical features 
of these diseases can accelerate discovery and improve the efficiency of translation, 
ultimately benefiting dogs and humans, and address unmet medical needs (Hayes et 
al., 1995; Reif et al., 1995; Khanna et al., 2006; Rowell et al., 2011; Marconato et al.,  
2013). 
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1.1 PRINCIPLES OF FLOW CYTOMETRY
The basic  principle  of  FC is  that  a  cells  population is  defined by its  morphological 
features  and  the presence/absence of  specific  antigens  (generally  called Cluster  of 
Differentiation  or  CD),  recognized  by  monoclonal  antibodies  labelled with 
fluorochromes and detected by the lasers.
Technical aspects 
The flow cytometer is an instrument that defines characteristics of cells or particles in 
a fluid stream as they pass through a light source (laser).
The main components of a flow cytometer consist  of a fluidic,  optic and electronic 
system, and a computer for the visualization of data (fig 1). 
The fluidic directs a liquid stream containing particles through the focused light source. 
Fluorescence results from the excitation of fluorochromes: the absorption of light by a 
population of these molecules raises their energy level to a brief excited state. As they 
decay from this excited state, they emit fluorescent light. The excitation laser focuses 
the  light  source  on  the  cells/particles,  where  collection  optics  (filters  and  mirrors) 
directs the light scatter of the cells/particle or various fluorescent signals of excited 
fluorochromes to an electronic network. 
The electronic network detects the light signals as it passes through the light beam and 
then converts the signals to a digital readout that is proportional to light intensity. The 
computer  records  the  digital  signals  from  the  electronic  detectors,  allowing  the 
operator to analyze the data and place it in one of several outputs (eg, histograms, dot 
plots, contour plots, density plots).
When the laser beam interrogates the cell, two types of light scatter occurs: forward-
angle scatter (FSC) and side-angle scatter (SSC) (Fig. 2-A). Forward angle scatter is the 
light that has diffracted around the cell and is proportional to cell size.
Side-angle scatter is 90-degree angle scatter and SSC is proportional to the internal  
complexity (granularity or nuclear lobularity) and surface texture of cells, as readily 
illustrated by higher SSC resulting from granulocytes than lymphocytes (Fig. 2-B). 
The unique light scatter properties of cells is used to distinguish subpopulations of cells 
based  on  their  size  and  internal  complexity.  Fluorescent  light  from  fluorochrome 
excitation is captured at the same angle as side-angle scatter. 
10
Commonly used fluorochromes are listed in Figure 3. Such an example, fluorescein 
isothiocyanate (FITC) and phycoerythrin (PE), absorb light at wavelengths of 488 nm 
and  emit  light  at  approximately  500  and  575  nm,  respectively,  which  can  be 
individually captured through the use of appropriate bandpass filters.
Flow cytometers may have a variety of laser configurations that dictate the types of  
fluorochromes that can be excited. One widely used flow cytometer is FACSCalibur 
from Becton Dickinson,  characterized by two-laser (argon and red diode) and four-
color detector system in which dyes in the green, orange, and red emission spectra are 
excited by the argon laser and detected by three photomultiplier tubes (PMT) referred 
to as FL1, FL2, and FL3 (see Fig. 1), whereas a red diode laser excites far red dyes that 
are detected by the FL4 PMT (see Fig. 1). 
Choice of antibodies
The availability of antibody clones conjugated with different fluorochromes allows the 
simultaneous evaluation of several cellular antigens. This multi-tube antibody panel, 
also  defined  as  "multicolor  approach",  is  extensively  adopted  for  flow  cytometric 
analysis, giving the more relevant performance than the use of individual markers. 
One of  the  advantages  of  a  multicolor  approach  is  that  the  higher  number  of 
fluorochromes is used for simultaneous analysis, the lower is the number of tubes in 
the antibody panel and the lower is the total number of cells required for the entire FC 
study; reagents and cells are thus utilized more efficiently. The analysis with three-four 
color is currently the standard for  human medicine, and is generally the best available 
for Veterinary Medicine in a clinical setting (Wood et al., 2007; Comazzi et al., 2017). 
Anyway,  a  careful  selection  of  unique  combinations  of  markers  is  based  on  their 
degree of specificity for the identification of a given cell lineage, maturation stage and 
aberrant phenotypes. However, a number of basic principles should be followed for 
the construction of the antibody panel:
-  Highly  expressed antigens  should  be  coupled  with  dim fluorochromes  and  dimly 
expressed  antigens  should  be  coupled  with  bright  fluorochromes.  This  principle 
ensures reasonable  sensitivity  for  each antigen and avoids  compensation problems 
due to excessively bright fluorescence.
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Figure 1: Essential components of the bench top flow cytometer (FACSCalibur). Fluidics (sheath fluid and 
waste  resevoir), optical bench including excitation optics (lasers) and collection optics (a, b, c, and  d), 
and the electronic network including  photo diode for FSC and detectors (SSC, FL1, FL2, FL3, and FL4 
PMTs) for side angle scatter and 4-fluorescent wavelengths. Red arrows represent the pressurized flow 
of the sheath fluid to the flow chamber (gray box where lasers interegate cells). (A) Inset of the sample 
tube (Wilkerson 2012).
Figure 2: (A) When a laser beam interrogates a cell. (B) Scatter plot (SSC-H vs FSC-H) of peripheral blood  
leukocytes from a healthy dog. Lymphocytes (Region 4, red gate) have the lowest forward and side  
scatter indicating their small size and low complexity, whereas monocytes are intermediate (R2 or green  
gate), and granulocytes are most complex (R3 or pink gate) (Wilkerson 2012).
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Figure  3:  Commonly  used  fluorochromes  and  respective  wavelengths.  PE=  phycoerythrin,  APC, 
allophycocyanin;  FITC,  fluorescein isothiocyanate;  PE,  phycoerythrin;  PerCP,  peridinin chlorophyll  
protein.
- At least one common reagent should be present in each of the tubes used for the 
evaluation  of  a  particular  lineage  to  allow  correlation  or  tracking  of  populations 
between  tubes.  For  exemple,  CD45  in  combination  with  side  scatter  allows  the 
identification  of  basic  hematopoietic  populations  (lymphocytes,  monocytes, 
neutrophils, myeloid and lymphoid blasts) and is commonly used to allow tracking of 
these populations between tubes in a panel.
-  Antigens  for  subpopulation  identification  within  a  particular  lineage  should  be 
combined  with  a  lineage  associated  antigen.  This  ensures  the  identification  of 
subpopulations within the appropriate  lineal context and aids in the recognition of 
nonspecific  patterns  of  antibody  binding.  i.e.  the  identification  of  CD4  and  CD8 
population should be combined with a T cell common antigen as CD5.
- Antigens that are differentially expressed with maturation within a particular lineage 
should  be  combined  to  recognize  maturational  stage  of  cells.  This  is  often  best 
accomplished by combining antigens preferentially expressed early in maturation with 
those  expressed  later  in  differentiation.  i.e.  for  B  cell  lineage,  CD21  should  be 
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combined with CD79a for the differentiation between early precursors (CD21- CD79a+) 
from naive mature stage (CD21+ CD79a+).
- Antigens differently expressed between closely related lineages may be used to allow 
improved lineage distinction. i.e. CD11b in combination with HLA should be combined 
for distinguish  neutrophils (HLA -) from monocytes (HLA +).
The  antibody  panel  to  be  used  in  multicolor  combinations  should  be  designed  to 
answer one or multiple relevant clinical questions. Usually,  a priori decision is made 
regarding the cell lineages and antigens to be evaluated, that is based on the type of 
specimen  and  other  available  information,  such  as  the  medical  indication  on  the 
requisition, clinical history, morphologic findings, results of other laboratory testing or 
prior flow cytometric testing. Therefore, a different strategy may be required in each 
situation, as the target cell population may not be known in advance or might have 
been defined previously.
In  the  former  situation,  is  generally  preferable  a  rapid  screening  step  based on  a 
limited number of antibodies directed at the identification of all relevant cell subsets in 
the specimen. Based on the results, a second antibody panel is performed with optimal 
markers  for  definitive  diagnosis,  classification,  and  prognosis.  This  approach  is 
generally more suitable in terms of efficiency and  cost reduction, providing a rapid 
screen for hematologic neoplasms of clinical specimens (Wood et al., 2006).
The  antibody  panels  for  screening  and  the  disease  classification  usually  fit  in  a  
diagnostic  algorithm that  may vary among laboratories.  A consensus panel  for  the 
diagnostic  approach  in  lymphoproliferative cancers  has  never  been  proposed  in 
Veterinary  Medicine,  although  the  European  Canine  Lymphoma  Network  (ECLN)  is 
working with the aim to provide guidelines (Comazzi et al.,  2017). 
Sample preparation and processing
Fresh specimens for FC fall into two broad categories: liquid samples (peripheral blood, 
bone marrow,  body fluids)  and solid  tissues  (lymph nodes,  spleen,  and  extranodal 
sites). Cells must be in liquid suspension for flow cytometric assay. Thus, peripheral 
blood cells or cells in suspension are well suited for the analysis, while solid tissue or 
adherent cell lines required processing into single cell suspension. 
At the time of collection, blood, bone marrow and body cavity fluids may be collected 
in  EDTA tubes,  while  tissue aspirates  should  be suspended in  a  tube  containing  a 
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preservation medium that may vary depending on the diagnostic laboratory (usually 
RPMI 1640 added with Na azide) (Liu et al., 2001).
The time between withdrawal and delivery to the laboratory, and the environmental 
conditions during transport are critical factors affecting the viability of the cells in the 
sample. Despite 48 hours from collection is generally considered the maximum storage 
time  for  retaining  adequate  viability,  samples  should  be  shipped  in  a  refrigerated 
packaging  and  analyzed  within  24  hours  to  preserve  cell  integrity  and  antigen 
expression  (McCoy 2010; McKenna et al., 2009; Nguyen et al., 2007).  This expedient is 
even more adopted when working with neoplastic cells: samples from tumors have a 
high cell turnover and cells are more prone to damage before 48 h (Jalla et al., 2004). 
Apart from the present work no specific information on canine samples regarding pre-
analytical variables possibly affecting the quality of FC results are currently available, 
but   ,  a recent study conducted on feline lymph nodes samples shows that major 
artifacts  influencing the likelihood of being processed was poor cellularity (Martini et 
al.,  2017).  For  this  reason,  adequate  sample  quality  and  sampling  conditions  are 
essential  factors  to  obtain  conclusive  results  from FC.  The  optimization  of  sample 
preparation steps is crucial to obtain good results from FC analysis mainly in samples 
shipped to a reference lab like in veterinary medicine. One of the goals of the present 
research is to provide the basis to create recommendations on how pre-processing the 
sample from canine neoplastic lymph nodes. 
Herein, the steps for labeling and processing samples for FC analysis will  be briefly 
described in order to identify possible source of bias that may influence the results of 
the analysis.
The first step when receiving a sample is to evaluate the cellularity of the samplesince  
a low cell yields limits the number of markers that can be analyzed.
Although red blood cells (RBC) have different size and light scatter characteristics then 
white blood cells (WBC), it could be useful to remove them before analysis, to obtain a  
good distinction of leukocytes population at the scatters. Red cells result in a large 
number of non-staining cells acquired that will make difficult the acquisition of events 
(cells),  in  particular  when  the  abnormal  population  is  poorly  represented  (Paietta 
2003). However, for lymph node samples the erythrocytes lysis could be unnecessary, 
unless gross hemodiluition. RBC lysis is usually made with osmotic damage using water 
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and ammonium chloride. This method is preferable then the use of density gradient 
methods, because preserves leukocytes integrity (Nguyen 2007).   
Then, a washing and centrifugation step is necessary to separate leukocytes from RBC 
debris, dead cells and other contaminants.
Once obtained a cell pellet of a sufficient number of leukocytes, cells are aliquoted into 
polystyrene  tubes  for  the  antibody  stains.  The  number  and  the  type  of  tubes  is 
dictated regarding the cell  lineages and antigens to be evaluated. Positive, negative 
and  isotypic  controls  preparation  depends  on  the  panel  of  markers  used.  These 
controls are useful to discriminate between right signals and erroneous signals that 
may  result  from  autofluorescence  of  cells,  lack  of  antibody  titration,  non-specific 
antibody  binding,  interactions  of  different  fluorochromes,  lack  of  instrument 
optimization, and many other factors (Hurley 2010).
A blocking reagent is applied prior to adding the specific antibodies to capture un-
specific binding sites on cells. For practical and economics reasons, the block usually 
consist in serum from bovine or equine, despite a serum of the same species is ideal.
Then,  antibody stains are performed: antibodies are added to tubes at  the correct 
working dilutions and incubations are generally performed at 4°C for 20-30'. 
Antibodies may be conjugated directly with fluorochromes (direct staining) or might be 
un-conjugated. In the second case, a two-steps procedure in needed (indirect staining), 
consisting  in  sequential  application  of  a  primary  antibody,  removal  of  unbound 
antibody, and application of a secondary fluorescent antibody.
Intracellular stains instead,  are directed to cytokine or cytoplasmic antigens.  It  is  a 
more  laborious  protocol  then  the  surface  antigen  detection  and  more  prone  to 
artifacts,  because cells have to be  fixed and permeabilized, to allow the antibodies 
enter  the membrane.  The fixation step with formaldehyde may alter  epitopes and 
increase  non-specific  bindings.  Also  in  this  case,  additional  negative  and  positive 
controls are essential. 
Once  cells  are  labeled  with  fluorescent  antibodies  the  samples  are  ready  for  the 
acquisition at the flow cytometer. The practice suggest to acquire at least  5000 or  
10,000 FC events to have a good representation of cells in the plots (Shapiro 2004).
Data analysis
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Multiparameter analysis and the possible selection of region of cells (gating) are some 
of the most important benefits of flow cytometry. 
Data interpretation is based on a graphical visualization of FC output, assessing the 
complex patterns formed by the shape and relative position of the cell  clusters on 
various graphics.
Data  could  be  represented  on  one-parameter  display  (histograms),  two-parameter 
display (cytogram, density, or contour plots) or three-parameter display (cloud plots) 
based on the operator’s choice (Fig. 4). 
The cytograms (dot plots), are useful in determining correlation between parameters 
and for determining gating strategies, as any other form of display. Typically, data are 
initially  displayed  in  2-dimensional  plots  of  FSC  versus  SSC  (also  known  as 
morphological  plot)(Fig.  5),  before  fluorescence  analysis.  In  blood  samples,  this 
configuration  separates  lymphocytes,  monocytes,  and  granulocytes  into  relatively 
distinct clouds. Then, dot plots to examine cell fluorescence of a gated population may 
be set to display FSC or SSC versus fluorescence or, alternately, fluorescence in one 
channel versus fluorescence in another channel. Which parameters are evaluated on 
dot  plots  depends  largely  on  the  nature  of  the  antigen  being  examined  and  the 
preference  of  the  operator.  Regarding  gating  strategies,  most  operators  generally 
prefer to use an elliptical  window then rectangles or parallelograms to select cells.  
Gates could be done on the bases of morphological or fluorescence features (Shapiro 
2004).  Based  on  the  specific  needs,  it  is  possible  to  analyze  only  lymphocytes 
population or to gate on a putative neoplastic population with peculiar morphological 
features.  Again,  analysis  restricted  to  CD45+  cells  may  be  useful  to  exclude  non-
leukocytes if RBC lyses are not performed (Comazzi and Gelain 2011).
A quadrant statistics is applied to get information from cells: four rectangular gating 
regions are created on the two-dimensional space of plots and information about cells 
lying in quadrants could be obtained. The operator can move the boundaries of the 
rectangular  gating  to  include  in  the  quadrants  the  cells  of  interest;  data  on  the 
percentage  of  a  given  population  and  the  fluorescence  intensity  of  markers  are 
achieved. 
Finally, information regarding the expression of a given antigen may be reported as 
percentage of positivity (or negativity), as  ‘‘dim or low,’’ ‘‘bright or high,’’ or ‘‘partially  
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expressed’ according the fluorescence intensity (Wood et al., 2007).  This is the most 
common  form  of  data  analysis  performed  to  two-parameter  distribution  (Shapiro 
2004).
The issue of how reporting FC for canine lymphoma has been debated in the context of 
the  European  Canine  Lymphoma   Network  and  some  guidelines  for  providing 
information of clinical usefulness will be edited (Comazzi et al., 2016).
However, the diagnostic interpretation of FC takes into account the other clinical and 
laboratory  data,  such  as  the  hemogram  findings  and  the  cytologic/morphologic 
features. A correlation between the FC findings and the available morphologic data 
should be performed in all  cases  (Mathiot  et  al.,  2006;  Comazzi  and Gelain,  2011; 
Ensani et al., 2012).  Knowledge of the pertinent clinical history, especially the type of 
therapy  (e.g.  corticosteroids),  is  also  useful  to  further  refine  FC  diagnostic 
interpretation.
Figure 4: Different types of data rappresentation of a FC output- A: histogram. B: cytogram. C: cloud plot 
(Shapiro 2004)
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Figure 5: morphological plot of a blood sample
1.2  FLOW  CYTOMETRY  APPLICATION  IN  THE  DIAGNOSIS  OF 
LYMPHOPROLIFERATIVE DISEASES
Canine  lymphoma/leukemia  are  malignant  disorders  derived  from  a  clonal 
proliferation  of  lymphoid  cells.  The  utility  of  FC  is  multifold  and  has  been  firmly 
established for lineage  assignment, analysis of cellular maturation and heterogeneity 
within the malignant cell population, as well as detection of minimal residual disease 
and monitoring  of  disease.  In  some groups  of  lymphoid  neoplasms,  FC  study  also 
provides prognostic information (Williams et al., 2008; Gelain et al., 2008; Comazzi et 
al., 2011; Marconato et al., 2011; Marconato et al., 2013; Martini et al., 2013; Rao et 
al., 2015; Mizutani et al., 2016; Riondato et al., 2016). 
Below are described the main aspects of canine lymphoma and leukemia in the dog 
and the possible FC application for immunophenotypic assessment.
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Lymphoma 
Lymphoma represents the most frequent hematopoietic  cancer in dogs,  making up 
83% of  all  hematopoietic  tumors  and  showing  significant  overlap  with  the  human 
disease (Marconato 2011; Richard and Suter 2015). Similarly to human non-Hodgkin’s 
lymphoma (h-NHL), canine lymphoma (c-NHL) is a heterogeneous group of lymphoid 
malignancies that have different subtypes and biological behaviors. 
Several information, starting from the signalment of the patient, have been found to 
be important factors for the definition of disease entities. 
Lymphoma  affects  primarily  middle-aged  to  older  dogs  and  many  studies  have 
reported variable occurrence of lymphoma by canine breed, showing that certain dog 
breeds  have  a  statistically  significant  increased  risk  of  this  tumor,  suggesting  a 
hereditary  compound  of  the  disease  (Modiano  et  al.,  2005;  Villamil  et  al.,  2009). 
Approximately 85% of all lymphomas in Boxers is comprised of T-cell, with >50% of 
these malignancies being CD3+ CD4+ in origin (Lurie et al.,  2004; Lurie et al.,  2008;  
Ponce et  al.,  2010).  In  contrast,  Basset  hounds and Cocker  spaniels  almost  always 
develop B-cell  lymphomas,  while  Golden retrievers has been described with a high 
incidence of both B-cell and T-cell lymphoma overall (19%) and T-zone lymphoma (TZL, 
40%), with differences in different geographical areas in United States (Modiano et al.,  
2005; Seelig et al., 2014); the high prevalence of Golden retriever seems confirmed in 
Japan but the same conclusions have not been reached by an European study  (Pastor 
et al., 2009). 
Regarding clinical signs, most animals are asymptomatic at the time of presentation, 
but sometimes there is a history of unspecific signs as weight loss, lethargy, anorexia, 
and  febrile  episodes.  A  common  lymphoma-related  hematologic  abnormality  is 
anemia,  followed  by  thrombocytopenia  seen  in  30%  to  50%  of  cases,  while  
lymphocytosis  is  uncommon  and  occurs  in  approximately  20%  of  affected  dogs 
(Madewell  and  Feldman,  1980;  Jain  1986). Anemia  has  been  also  reported  as  a 
negative prognostic factor influencing survival and response to therapy (Abbo et al., 
2007)
The most important clinical finding at presentation is the enlargement of lymph nodes: 
it  is  reported  that  80%  of  dogs  develops  a  multicentric  form  characterized  by 
superficial lymphadenopathy (Vail and Young, 2013). 
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When a dog presents to the veterinarian with lymphadenomegaly,  the microscopic 
evaluation of lymph node fine needle aspirate is still the first approach, mainly because 
is minimally invasive and cost effective. Despite a classification of lymphoma subtypes 
and different prognosis have been reported for a number of well described cytological 
entities (Ponce et al., 2004), this  morphological diagnosis does not provide sufficient 
information to the clinicians for the management of the patient. Thus, a cytological  
evaluation is usually followed by ancillary  techniques such as immunohistochemistry, 
molecular biology and FC (Dong et al., 2001; Comazzi and Gelain, 2011). 
Although histopathologic  evaluation of  architectural  patterns  have been historically 
considered as the gold standard for lymphoma classification, using WHO scheme, the 
advent of FC in addition of cytology allowed to putatively diagnose and classify most  
canine  lymphoma  subtypes  that  have  a  characteristic  cytomorphology  and 
immunophenotype  (Gelain  2008;  Comazzi  and  Gelain,  2011;  Martini  et  al.,  2013; 
Seelig  et  al.,  2014). Specific  studies  on  the  diagnostic  performances  of  different 
techniques  in  defining  different  lymphoma subtypes  are  still  lacking  in  dogs,  but 
according to a survey conducted in US, histopathology (Regan et al., 2011) is required 
just on a small percentage of dogs with lymphoma prior chemotherapy. 
When the WHO scheme was applied to the dog, it was found that the vast majority of 
lymphoma  cases  consisted  of  only  five  histological  subtypes:  diffuse  large  B-cell 
lymphoma (54%), marginal zone (B-cell) lymphoma (4%), peripheral T-cell lymphoma 
not  otherwise  specified  (16%),  nodal  T-zone  lymphoma (14%)  and T  lymphoblastic 
lymphoma (5%) (Valli et al., 2011). Apart from WHO, among the other classification 
schemes available for canine lymphoma, just the updated-Kiel classification appears of 
some clinical usefulness according to a recent paper (Sayag et al., 2018). This scheme is  
mainly based on morphologic appearance of neoplastic cells and tissue architecture is 
just minimally considered, that’s why updated-Kiel classification is generally preferred 
for the use in cytology. Some papers have attempted a correlation between WHO and 
updated-Kiel (Ponce et al 2010) (fig. 6) .
Studies  evaluating  lymphoma  in  dogs  by  FC  have  generally  confirmed  the 
predominance  of  one  type  of  B-cell  lymphoma  and  identified  a  variety  of  T-cell 
phenotypes.  Nevertheless,  a  quantitative  and  a  qualitative  evaluation  of  antigen 
expression by FC resulted to be useful to identifying aberrant subtypes and further  
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subclassify lymphomas into clinically  relevant subcategories (Wilkerson et al.,  2005; 
Gelain et al., 2008). 
Anyway, the knowledge of features typical of an healthy lymph node are fundamental  
for the recognition of neoplastic conditions. Generally, polyclonality and the absence 
of phenotypic aberrancies characterize a benign sample. It is important to be aware, 
however, that the absence of abnormalities by FC analysis does not necessarily exclude 
the presence of a lymphoma; sampling errors or selective loss of neoplastic cells during 
preparation, or other tumors that may not be recovered in the cell suspension, could 
result in a "false picture" dot plot (Nguyen 2007). 
In a normal lymph nodes, the majority of cells express CD45 (around 90%), with a  
degree of expression (fluorescence intensity) that vary among lymphocyte population 
(Comazzi et al., 2006). T-lymphocytes expressing CD3, CD4, or CD8 represented about 
60 %, 40%, or 20% of the total cells, whereas B-lymphocytes expressing either CD21 or 
surface IgM represented 30% or 15%, respectively. CD34 is not expressed on mature 
lymphocytes, CD14 (monocytes) positive cells are few (4%) while granulocytes (CD11b) 
are rare (2-3%) and attributable to neutrophils or eosinophils (Wilkerson 2005; Rutgen 
2015). 
Small  lymphocytes could be distinguished from large lymphocytes by forward light 
scatter. According FSC channel, both small and large lymphocytes are present in B and 
T cell populations: usually small cells fall between 200 and 400 FSC, while medium to 
large cells  fall  over  400 FSC;  the size  parameters may vary among flow cytometer 
according  the  calibration  of  the  instrument  (Wilkerson  et  al.,  2005;  Rutgen  et  al., 
2015). 
When interpreting the staining patterns of tumor cell preparations, a cutoff value of 
60% of the cells labeling for a specific cell  marker is usually used (Wilkerson et al.,  
2005). This guideline is similar to the criteria used for cytological assessment in which a 
diagnosis  of  lymphoma  can  be  confidently  made  when  >50%  of  the  cells  have 
immature features (Cowell et al., 1999). 
However, this cut-off value is very high and may provide false negative results in early 
stage lymphomas or in neoplastic lymph nodes with a mixed population of cells, such 
as T-cell rich B-cell lymphoma, or with a high percentage of residual resident lymphoid 
cells, such as in  follicular lymphomas.
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B-cell-origin lymphomas in the dog are characterized by the expression of the markers 
CD21, CD79a, CD20, IgM, MHC class II (Wilkerson 2005; Gelain et al., 2008). Some case 
do not express CD21 but expressed CD79a and IgM, likely representing an arrest at an 
immature  stage  of  B-cell  maturation:   CD79a expression  precedes  immunoglobulin 
heavy-chain  gene  rearrangement  during  B-cell  development  and  is  expressed  in 
lymphoma/leukemias arrested at the pre-B-cell stage (Chu and Arber, 2001) (Fig. 7). 
Cell size observed by morphological evaluation is usually confirmed by the FSC scatter. 
Centroblastic B-cell lymphoma and pleomorphic large B-cell lymphoma are the most 
common subtypes and show higher mean FSC. B-macronucleolated medium size cells 
usually show an higher size at FC then on slides, maybe due to the fact that cells on 
slides  rapidly  undergo  dehydratation  and  rigidity  (Gelain  et  al.,  2008).  Low-grade 
lymphomas and lymphoblastic lymphoma are characterized by low FSC, thus gating on 
neoplastic  populations  is  quite  difficult  on  scatter  cytograms  alone;  therefore,  the 
detection of a prevalent immunophenotype and quantitative antigen expression may 
be of particular value to confirm the neoplastic origin (Comazzi et al., 2006; Comazzi 
and Gelain, 2011). 
Cell  size is also reported to be partially related to the behaviour of the disease.  A 
recent study on B-cell lymphomas disclosed that patients with large tumor cells were 
2.8 times more likely to die compared with those with small tumor cells (Rao et al., 
2011); this result could be explained by the fact that large cells might correspond to a 
more immature cell type that has a more aggressive neoplastic behavior.
Among the T-cell  lymphomas,  small  clear  cells,  pleomorphic  large  and mixed cells, 
large  granular  lymphocytic  cells  and  lymphoblastic  are  cytologic  subtypes  most 
represented in the dog (Gelain et al., 2008; Ponce et al., 2010). 
T-cell  lymphomas express a combination of CD3, CD5, CD4, and CD8 markers,  with 
CD3+CD4+CD8- the most frequent subtype (Fig. 7). CD3+CD4+CD8+ phenotype profile 
is instead indicative of an early thymocyte differentiation stage. One study reported 
how FC of mediastinal mass aspirates may provide a definitive diagnosis of thymoma 
or ymphoma: samples containing ≥ 10% lymphocytes coexpressing CD4 and CD8 was 
reported  to  correlate  with  a  histologic  diagnosis  of  thymoma,  whereas  thymic 
lymphomas expressed either CD4/CD8 or B-cell antigens,  demonstrating that FC is a 
useful tool for discriminating mediastinal masses (Lana et al ., 2006). 
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Figure 6:  Updated Kiel Classification33 of 608 Canine Lymphomas With Possible Correlation With the 
World Health Organization Human Classification (Ponce et al., 2010)
In addition to the determination of the immunophenotype, the expression of specific 
markers as  well  as  the quantification of  the expression are found to be consistent 
predictors of poor outcome. 
Rao  et  al.  (2011)  found an  association  between low class  II  MHC levels  and  poor 
survival, which is a parallel finding in people with diffuse large B-cell lymphoma, where 
Class II MHC expression is a strong predictor of outcome (Rimsza et al., 2007). Similar  
results  have  been reported for  T  cell  CD4+ lymphoma in  a  recent  study  exploring  
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different  immunotypes  of  T  cell  high  grade  lymphoma  and  their  association  with 
outcome (Deravi et al., 2017). 
 
Figure 7: Common antibodies used to phenotype canine hematopoietic neoplasms (Rout and Avery, 
2017)
Again,  a  recent  publication  has  explored  the  clinical  relevance  of  CD25  marker  in 
canine  lymphoid  tumors,  finding  that  CD25-positivity  in  the  lymph  node  was 
significantly  higher  in  dogs  with  high-grade  B-cell  lymphoma  and  TZL,  and  the 
progression-free survival was significantly shorter in high-grade B-cell lymphoma with 
CD25-high  expression  (Mizutani  et  al.,  2016).  Also  these  results  are  partially  in 
agreement with human's literature (Fujiwara et al., 2013).
Generally, studies taken together exhibit that in dogs high grade T-cell lymphomas are 
usually linked to a poor response to therapy (Wilkerson et al.,  2005),  with survival 
times being often shorter than the B-cell counterpart  (Ponce et al., 2004; Morris and 
Dobson, 2001). However, some B-cell lymphoma like the Burkitt type result in short 
survival time, while some T-cell lymphomas,  such as TZL, generally show a long-term 
survival (Seelig et al., 2014). 
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Studies  focused  on  the  prognostic  value  of  aberrant  phenotypes  have  also  been 
proposed. (Williams et al., 2006; Gelain et al., 2006; Comazzi et al., 2008; Seelig et al.,  
2014). The most common aberrant patterns in canine lymphomas are reported to be 
the  co-expression  of  T  and  B  antigens  (CD3  and  CD21  or  CD3  and  CD79a),  the 
expression of CD34, the co-expression of CD4 and CD8 on T cell lymphomas, and the 
under  expression  of  CD45  and  CD18  (Wilkerson  et  al.,  2005;  Guija  et  al.,  2006; 
Riondato et al., 2006; Gelain et al., 2008; Comazzi et al., 2011). 
Several works reported many T lymphocyte aberrancies detected by FC, thanks to the 
availability of different monoclonal antibodies for T-cell characterization (Wilkerson et 
al., 2005; Gelain et al., 2008) (Fig). 
On the contrary, few antibodies are available for canine B-lymphocytes: consequently, 
a  reduced  number  of  B-cell  antigens  can  be  tested  and  many  aberrancies  would 
remain undetected. For this reason,  validation of  new anti-canine or  cross-reacting 
antibodies is needed, and in the future may permit the identification of aberrancies in 
canine B-cell neoplasms too. 
Neoplastic cells with aberrant antigen expression could be easily detected in different  
tissues,  thus  allowing  for  the evaluation,  staging  and a  sensitively  identification  of  
minimal residual disease (MRD) by FC. 
The WHO guidelines for canine lymphoma staging provide five stages for classify the 
spread  of  the  tumor  and  include  the  involvement  of  lymph  nodes  (stages  I-III), 
spleen/lever  (stage  IV),  peripheral  blood/bone  marrow or  any  other  non lymphoid 
tissue (stage V). Tumor at V stage is,  according to some authors, correlated with a 
poorer outcome and a shorter survival time then stages I to IV (Vail and Young, 2013; 
Marconato et al., 2011). Information regarding the distribution of lymphoma makes it  
possible to assist in the formulation of therapeutic protocols, but also to accurately re-
stage dogs at the end of a therapy session and to monitor the response to treatment,  
based on the evaluation of reduction in size of lymph-nodes and the assessment of a 
residual neoplastic population in LN, PB and BM (minimal residual disease, MRD) (Vail  
2010;  Marconato  2011).  Despite  the  prognostic  significance  of  BM  infiltration  in 
patients  affected  by  large  B  cell  lymphoma has  been established by  some studies 
(Marconato et al., 2011; Marconato 2013), to date the BM evaluation is not routinely  
performed (Davies et al., 2017). The issue of whether the examination of BM should be 
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performed or not is still under debate: one study declaim that BM involvement does 
not affect therapeutic decision and stage migration (Flory et al 2007); however, cases 
with  BM  involvement  that  do  not  correlate  with  PB  abnormalities  are  reported 
(Martini et al., 2015) and, on the contrary, the finding of circulating blast cells does not 
necessarily imply marrow invasion as their presence may be attributable to ‘overspill’  
(Chapel  et  al.,  2009).  Thus,  BM evaluation should be included in routine staging in 
order not to miss infiltrated samples and to improve classification. 
Several methods are used for the determination of neoplastic infiltration in tissues, 
mainly microscopic evaluation, FC and molecular biology techniques. The advantage of 
FC in  tumor staging and MRD assessment is  the high sensitivity  in  detecting small 
infiltration percentages: a recent publication reports the high performance of FC for  
the  quantification  of  large  B-cells,  providing  the  cutoff  of  0.56%  and  2.45  %  in 
peripheral  blood  and  bone  marrow,  respectively,  to  safely  discriminate  between 
infiltrated and un-infiltrated (Riondato et al., 2016); however, specificity depends opon 
the type of lymphoma and the characteristics of the neoplastic cells. Large lymphomas 
or aberrant phenotypes are easily recognized (Martini  et al.,  2015; Riondato et al.,  
2016), while small cell lymphomas, especially those of B lineage or T CD4+, may be 
difficult  to  differentiate  from  normal  lymphocytes.  In  these  cases,  molecular 
techniques such as polymerase chain reaction amplification of antigen receptor genes 
(PARR) are likely more sensitive and useful than FC for the determination of neoplastic 
infiltration (Lana et al., 2006), although PARR is yet unable to quantify the extend of 
infiltration. Thus, the use of FC and PARR is suggested in conjunction to improve the 
accuracy of  clinical staging of lymphoma and detection of MRD in dogs (Aresu et al., 
2014). 
An example of a small cell lymphoma easily recognized by FC is small clear cell/T-Zone 
Lymphoma (TZL). TZL has a peculiar T cells immunophenotype CD45 negative, that can 
be used to readily identify this disease with 2 color flow cytometry, obviating the need 
for tissue biopsy (Martini et al., 2013; Seelig et al., 2014).
In human medicine the identification of persistent disease or relapse is currently based 
on  imaging  (positron  emission  tomography  (PET)  and  computed  tomography  (CT) 
scanning  are  the  principal  tools)  and  clinical  evaluations  (Thompson  et  al.,  2014; 
Huntington et al., 2015), but novel methods based on polimerase chain reaction (PCR) 
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and next generation sequencing (NGS) are now being studied with promising results: 
These innovative tools  allow to detect and quantify circulating tumor DNA (cfDNA) 
released by  neoplastic  cells  subject  to destruction and necrosis.  This  method,  also 
known  as  "liquid  biopsy",  offer  MRD  measurement  with  excellent  sensitivity 
(Narayanet al,  2012; Newman et al,  2014; Roschewski  et al, 2015, Rossi et al., 2017; 
Spina et al.,  2018). 
In  veterinary  medicine,  we  are  still  far  away  from  these  type  of  diagnostic  
investigation, although the potential value of cfDNA in the prognosis is reported in 
dogs affected by lymphoma and mammary tumor (Shaefer et al., 2007; Beffagna et al., 
2017).
In  conclusion,  FC  with  a  multi-parametric  approach  for  the  diagnosis  of  canine 
lymphoma,  contributes  to  the  evaluation  of  cell  lineage  as  well  as  to  antigen 
quantification  and  monitoring  of  the  disease,  and  provides  useful  information  for 
outcome prediction. The use of this technique will be further enhanced by wider panel  
of canine-specific marker antibodies and by a careful description of tumor entities.
 
Leukemia 
A dog presenting with lymphocytosis may be a dilemma for clinicians. The diagnosis 
can be quite challenging, because leukemia is associated with nonspecific clinical signs 
and  sometimes  mild  hematologic  abnormalities  may  be  difficult  to  interpret.  To 
accurately diagnosed a lymphoid leukemia must be considered several factors, such as 
signalment, history, clinical findings, cell morphology and the immunophenotype. 
Historically,  the  diagnosis  of  leukemia  relied  only  on  the  morphological  analysis. 
Lymphoid leukemias are divided into acute (ALL) or chronic leukemias (CLL), according 
the stage  of  maturation  of  neoplastic  cells  and the evolution  of  the diesease:  CLL 
produces cells that are morphologically similar to normal small, mature lymphocytes.  
ALL,  on  the  other  hand,  originates  from  more  immature  cells  and  shows  cells 
morphologically resembling large blast cells.
Because the diagnosis and precise classification of leukemia by morphologic criteria 
alone is limited (Davis et al., 1997), immunophenotyping via FC is to date the preferred 
method  for  the  characterization  of  leukemic  cells  in  veterinary,  and  is  the  gold 
standard for classification of human leukaemias (Avery and Avery, 2007). 
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Leukemias in dogs  are heterogeneous disease comprising approximately  10% of  all 
haematopoietic tumor, with survival  ranging from days  to years,  depending on the 
subtype. However, the real incidence of these tumors in the dog is imprecise, most 
likely  because  underdiagnosed  due  to  the  rapid  clinical  course  (in  ALL)  and/or 
nonspecific clinical signs (Weiss and Wardrop 2011; Vail and Young, 2013). 
Dogs with CLL are typically older than those with ALL: from several studies it emerges  
that the average of dogs with CLL is 10-12 years (range 3-19) (Comazzi et al., 2011;  
Bromberek et al., 2016; Moore and Vernau, 1999), compared with 7-8 for ALL cases 
(range 7 months-16 years) (Novacco et al.,  2015; Adam et al.,  2009; Bennett et al., 
2016; Tasca et al., 2009). Interesting, this is in agreement with human medicine, where 
the prevalence of acute lymphoblastic leukemia is observed in children and chronic 
leukemia  affects  older  patients  (Chiaretti  et  al  2013;  Rai  et  al.,  1975).  Some  case 
reports  and  retrospective  studies  also  suggest  that  large-breed  dogs  are  more 
susceptible to acute leukemia (Tasca et al., 2009; Adam et al., 2009; Novacco et al.,  
2015),  with  a  significant  over-representation  of  Golden  Retrievers  and  German 
Shepherd (Adam et al., 2009; Novacco et al. 2015; Bennett et al., 2016; Tasca et al.,  
2009), while one study shows that B-cell CLL is over-represented in small-breed dogs 
(Bromberek et al., 2016).
Regarding clinical signs, they may vary dramatically, also depending on clinical stage. 
The  most  frequent  owner  complaint  at  presentation  is  lethargy;  other  common 
abnormalities include reduced appetite, polyuria,  polydipsia,  and sporadic vomiting. 
Usually,  dogs  with  CLL  present  with  a  long  history  of  recurrent  nonspecific  signs. 
Physical  examination may reveal  splenomegaly,  hepatomegaly,  fever or  generalized 
lymphadenopathy (Vail and Young, 2013). Lymphadenopathy associated with leukemia 
is usually milder than that of lymphoma, in which the lymph nodes are often massively 
enlarged (Couto 2003).
CBC at diagnosis  could shows hematological  abnormalities referred to leukocytosis, 
anemia and thrombocytopenia; lymphocytosis is usually much more extreme then that 
associated with other conditions, with lymphocyte counts ranging from 6,000 to well 
over 500,000/μl (Vail and Young, 2013; Novacco et al., 2015). Anemia is found in 80% 
of cases; in some studies it is reported to be significantly more severe in ALL cases then 
in CLL (Tasca et al., 2009) and to be related to a shorter survival time (Novacco et al.,  
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2014). Thrombocytopenia is another well-recorded haematological abnormality: it is 
reported that dogs with ALL had significantly higher thrombocytopenia grades than 
their counterparts with CLL (Tasca et al. 2009; Leifer and Matus, 1986). 
Generally  speaking,  acute leukaemias present with more profound cytopenias  than 
their chronic counterparts (Morris and Dobson, 2001). 
From a clinical perspective, it is crucial to identify neoplasms of precursor from those 
of mature lymphoid cells: the prognosis of acute leukemia is very poor compared to 
CLL, that is generally a slowly progressive disease (Novacco et al., 2015; Adam et al.  
2009; Comazzi et al., 2011; Bromberek et al., 2016).
For this purpose, immunophenotyping via FC is a valuable tool to distinguish between 
acute and chronic leukemia, as well as the differentiation between acute leukemias 
and a leukemic phase of lymphoma.
The  knowledge  of  circulating  lymphocyte  of  normal  dogs  is  fundamental  for 
determining if a particular subset has expanded. The major fraction of lymphocytes in 
peripheral  blood are of  T  lineage (80%),  with T helper cells  (CD4+)  outnumber the 
citotoxic T cell (CD8+), while the B cell are about 15%. The remaining fraction is usually 
composed by NK cells and double negative T lymphocytes (CD4-CD8-)  (Byrne et al., 
2000; Workman and Vernau 2003). 
Based  on  the  above  statement,  lymphoid  leukemia  should  be  considered  when 
lymphocytes  present  an  homogeneous  immunophenotype,  when atypical  lymphoid 
cells are observed or when a phenotype typically less represented has increased (Vail 
and Young, 2013). However, in certain situation could be complicated distinguishing 
between  reactive  proliferation  and  neoplastic  expansion.  Some  infectious  or 
inflammatory diseases can also, occasionally, result in expansion of a phenotypically 
homogeneous population of lymphocytes. Differential diagnosis should be taken into 
consideration,  including  chronic  ehrlichiosis,  postvaccinal  response,  IL-2 
administration,  transient physiologic lymphocytosis.  However, in cases in which the 
phenotype data are equivocal,  clonality testing using PARR assay could be a useful  
second step (Burnett et al., 2016). On the other hand, an aberrant antigen expression 
can provide a definitive diagnosis of leukemia because reactive lymphocytes generally  
retain expression of the normal constellation of antigens.
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The  surface  glycoprotein  CD34,  which  is  expressed  on  immature  hematopoietic 
progenitors and not present on more mature and differentiated cells may help the 
distinction  between  CLL,  ALL  and  lymphoma.  Therefore,  ALL  (CD34+)  can  be 
distinguished  from  CLL  (CD34-)  and  lymphoma  (CD34-)  (Vernau  and  Moore  2009; 
Wilkerson  et  al.,  2005;  Gelain  et  al.,  2008).  However,  some  lymphoma  may 
occasionally show CD34 positivity. This expression is considered aberrant when blood 
and bone marrow are not infiltrated by neoplastic  cells  and the remaining antigen 
pattern suggests a neoplasm of mature lymphoid cells (Gelain et al., 2008). Moreover, 
a proportion of  ALL  are recognized to be CD34 –;  the expression of  the marker is  
reported to range from 37 to 76% of ALL (Adam et al., 2009; Bennett et al.,  2016). In 
these cases, other laboratory and clinical  features can help discrimination between 
lymphoma  or  leukemia,  based  on  the  fact  that  the  published  criteria  for  acute 
leukaemia  diagnosis  required  >30% morphologically  blast  cells  in  either  peripheral 
blood or bone marrow (Modiano and Helfand, 2000; Grindem and Neel, 2002; Adam et 
al., 2009). Therefore, the expression of CD34 marker is not conclusive of ALL.
To  investigate  new  markers  for  leukemia  diagnosis  and  classification,  our  group 
evaluated CD44 expression on peripheral blood of dogs affected by precursor cell and 
mature cell  leukemia,  finding  a  significantly  higher  MFI  of  the antigen  in  leukemic 
samples compared to controls and a higher expression was found in AL in respect with 
CLL,  underling  the  utility  of  this  marker  for  the  identification  of  canine  leukemias 
(Gelain et al., 2014) 
Both types of lymphoid leukemia may arise from B, T, or NK cell clones. In humans, B-
cell neoplasia predominates and represents 95% of CLL cases; in contrast with human 
counterpart,  B-cell  neoplasia  is  less  common  than  T-cell  neoplasia  in  canine  CLL, 
representing less than 30% of cases (Moore and Vernau, 1999; Tasca et al., 2009).  T-
CLL  with  CD3+  CD8+  phenotype  has  been  reported  as  the  most  frequent  form, 
representing over 70% of CLL, mainly showing LGL morphology (80% of T-CLL). T-CLL 
shows a classic indolent behavior and long survival time, atypical CLL is characterized 
by  very  aggressive  behavior  and short  survival,  while  B-CLL  may be  considered an 
intermediate behavior, with old dogs surviving quite long, and young dogs showing a 
more aggressive course. From a study emerged that the range of survival time for 17 
dogs affected by B-cell CLL was from 20 to >800 days (Comazzi et al. 2011). 
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On the contrary, the true prevalence of B- vs T-cell ALLs in dogs should be considered 
uncertain. Bennett et al.  (2016)  found a predominance of T-cell  ALLs (15 of 20).  In 
contrast, in 2014 we published that of 71 dogs with acute leukemias, when myeloid 
leukaemias were excluded from analysis, B-cell origin constituted 43% and T-cell origin 
constituted  20%  (37%  were  undifferentiated)  (Novacco  et  al.,  2015).  In  other  two 
publications reporting on flow cytometric assessment of canine leukaemias, 15 of 25 
and 47 of 51 ALL cases were B-cell-origin (Adam et al., 2009; Tasca et al.,  2009). 
Regarding  the  prognostic  aspects,  while  it  is  well  established  that  for  the  chronic 
counterpart the T-cell lineage have a better behaviour, it is instead unknown whether 
the same holds true for ALL, since few studies are currently present in literature and 
insufficient dogs had definitive immunophenotyping.
Despite the advances in classification, a separate clinical staging system has not been 
developed for  chronic  lymphocytic  leukemia.  Currently,  all  dogs  with leukemia  are 
classified as  stage V based on the WHO staging system for lymphoma.  Although a 
specific prognostication system for CLL has been used in humans, comprising clinical-
pathological (Rai et al., 1975; Binet et al., 1981), molecular (IgVH mutation status)  and 
flow cytometric  (ZAP70  and CD38)  parameters (Damle et al.,  1999; Capello et  al., 
2004; Sulda et al., 2012), it has not been evaluated in the dog. The group of Colorado 
State  University  recently  published  a  study  aimed  to  describe  the  IgHV-D-J 
rearrangements of 55 canine patients with CLL, including non-Boxer and Boxer dogs. 
The majority of non-Boxers (75%) had mutated IGHV genes, whereas the majority of 
Boxers (79%) had unmutated IGHV genes. Despite the prognostic significance was not 
investigated,  the  results  provide  bases  for  further  studies  aimed  to  the  risk 
stratification of patients (Rout et al., 2018).
However, both CLL and ALL are poorly characterized in dogs and few pathogenic and 
prognostic studies are available in the literature (Usher et al.,  2009; Comazzi  et al., 
2011; Aricò et al., 2013; Giantin  et al.,2013).
In conclusion, the application of FC in canine leukemia is useful for diagnosis and cell 
lineage.  In  CLL  may  bring  also  prognostic  information.  However,  the  strong 
heterogeneity of  leukemias  makes necessary to find  possible molecular  biomarkers 
associated with different survival times or disease evolution.
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2. Aim
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The  utility  of  flow  cytometry  and  its  importance  in  the  diagnostic  pathway  of 
hematopoietic tumors is even more relevant in both human and dog. Several studies 
have demonstrated that some flow cytometric  findings may play also a role in the 
prediction of treatment free survival and survival time.
The  last  15  years  of  literature  in  the  issue  of  canine  lymphoproliferative  tumors 
demonstrates  that  strides  have  been  made  to  improve  classification  and 
understanding  of  pathogenesis  through  immunophenotyping,  yet  classification, 
prognostic relevance and choosing appropriate therapy remains challenging. 
Diffuse large B cell lymphoma is the most diffuse lymphoma subtype and, in the past  
years,  several  studies  from  our  lab  and  international  research  groups  have  been 
performed  to  better  characterize  this  tumor  in  terms  of  immunophenotyping 
(including flow cytometric aspects), pathological and molecular aspects. In the present 
thesis we decided to focus on some less investigated lymphoma/leukemia subtypes, 
starting from the experience collected during the last 10 years of FC diagnostic service, 
and trying to investigate some aspects that could be interesting from a biological  point 
of view. 
In  particular,  the  aim  of  the  present  research  project  was  to  characterize  specific  
canine lymphoma and leukemia subtypes within the application of flow cytometry, to 
describe  the  power  of  this  technique  for  diagnostic  purpose  and  to  identify  new 
biomarkers for risk stratification of patients, thus helping the oncologists to undertake 
the better manage of the patient.
To the aim, either retrospective e prospective approaches were adopted, depending 
on  the  nature  of  the studies.  To  draft  a  complete  biological  profile  of  tumors,  an 
integration of immunophenotypic, clinical and pathological data was performed. 
The main technique reported and utilized in the present thesis is flow cytometry, but  
other molecular tools have been used to better identify antigens of interest (when 
monoclonal  antibodies were not  available) and to explain the origin of  phenotypic 
aberrancies (within the analysis of the gene and the transcript of the antigen). 
Specific objectives were: 
- to define preanalytical variables which could affect the power of flow cytometry for  
the evaluation of lymph node samples in lymphoma diagnosis; 
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-  to define lymphoma entities from a pathological,  phenotypic and clinical  point of 
view and to improve the definition of the prognosis, with particular attention on T-
zone Lymphoma and  Marginal Zone Lymphoma. These two entities were chosen for 
the paucity of  information available  in literature,  in spite of  the relative frequency 
among canine lymphomas and the peculiar biological behavior; 
- to evaluate the application of new markers (ZAP70, CD25, ki67 and CD38) for B-CLL 
diagnosis and prognosis. 
To  better  exhibit  the  studies,  the  following  chapter  will  be  subdivided  into  four 
sections: 
-  EFFECTS  OF  PRE-ANALYTICAL  VARIABLES  ON  FLOW  CYTOMETRIC  DIAGNOSIS  OF 
CANINE LYMPHOMA: A RETROSPECTIVE STUDY
- CANINE T-ZONE LYMPHOMA: CLINICAL AND PATHOLOGICAL CHARACHTERIZATION
- NODAL MARGINAL ZONE LYMPHOMA: INSIGHT INTO THE BIOLOGICAL BEHAVIOUR
- EVALUATION OF PUTATIVE PROGNOSTIC MARKERS IN CANINE B-CLL: A PRELIMINARY 
STUDY 
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3. Studies
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3.1  EFFECTS  OF  PRE-ANALYTICAL  VARIABLES  ON  FLOW  CYTOMETRIC 
DIAGNOSIS  OF CANINE  LYMPHOMA:  A  RETROSPECTIVE  STUDY  (2009–
2015)
Background
In human medicine flow cytometry is widely used to immunophenotype leukemia and 
lymphoma cells. In veterinary medicine this technique is in rapid developmente and 
spread but, in contast with human medicine, a low number of facilities offer a flow 
cytometric  services  with  an  adequate  skill  in  canine  onco-haematology.  As  a 
consequence,  it  constrain  to  use  reference  labs  to  which  samples  coming  from 
different  institutions  and private  vets  are  shipped.  We hypothesized  that  different 
sampling  techniques,  shipping  and  storage  conditions  might  bias  the  results  and 
influence the diagnostic performance of FC. To the authors’ knowledge, only one study 
on the influence of pre-analytical variables on diagnostic performance of FC is available 
in cats (Martini et al., 2017), but a study evaluating the effects of such variables in a  
high number of dogs is still lacking. The aim of this retrospective study was to assess 
whether pre-analytical  variables may influence the diagnostic  utility of lymph node 
(LN)  FNA  samples  from dogs  with  clinically  suspected  lympho-proliferative  disease 
analysed by FC.  The goal  was to create recommendations for sampling techniques, 
sample  storage  and  shipping,  in  order  to  decrease  pre-analytical  errors,  and  to 
increase the diagnostic utility of FC for the diagnosis of lymphoma and leukaemia in 
dogs.
Material and Methods
Inclusion criteria 
The FC database of the Department of Veterinary Medicine, University of Milan, Italy, 
was searched retrospectively and canine cases were identified over a period of six 
years (2009–2015). The inclusion criterion was a LN FNA submitted for flow cytometric 
immunophenotyping.  If  other  sample  types,  such  as  peripheral  blood  (PB),  bone 
marrow (BM) aspirates, body cavity effusions, FNA from mass lesions, spleen, liver or 
other tissues, were submitted, these cases were included in the study only if a LN FNA 
from the same animal was analysed, regardless of the diagnostic pathway used and 
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what  tissue  (e.g.  PB  or  BM for  leukaemias)  was  considered  first  in  the  diagnostic  
pathway. Exclusion criteria included cases composed of tissues other than LN aspirates 
and cases submitted for minimal residual disease analysis.
Sample collection
For flow cytometry analysis, LN FNA was resuspended in 1 ml RPMI 1640 with 5% fetal 
bovine serum (FBS) and 0.2% sodium azide,  refrigerated at 4–6°C and shipped to the 
laboratory within 24 h of sampling with a cold pack in the envelope to maintain sample 
cooling. Peripheral blood (PB) and bone marrow (BM) were submitted in  EDTA tubes. 
At admission, samples were examined visually and cellularity was evaluated using an 
automated analyser (XT-2000iV, Sysmex). Cellularity was considered to be suitable for 
analysis if the cell concentration in 1 mL was > 5 x 109 cells/L (corresponding to > 5 x 
106 cells in total), whereas samples with < 1  109 cells/L (corresponding to < 1 x 106 cells 
in total) were excluded from processing, although slight variability may have occurred 
due to the preferences of the operator dealing with the sample. The erythrocyte lysis 
step  was  not  considered  to  be  necessary  for  LN  FNA  samples  unless  gross 
hemodilution was detected at visual inspection. For PB and BM samples, red blood 
cells were lysed by adding a lysis solution containing 8% ammonium chloride. 
Flow cytometry
The panel of antibodies applied to samples was adapted over time as more conjugated 
antibodies  against  canine  leucocytes  became  available.  Samples  processed  before 
2011  were  analysed  using  mainly  a  two-colour  approach.  Starting  from  2011,  a 
multicolour approach was applied, with the addition of CD45 as tracking label in all 
tubes. 
The  diagnostic  algorithm  varied  throughout  the  years,  but  a  basic  panel  included 
antibodies against CD5, CD21, CD34, propidium iodide and CD45. On the basis of the 
staining results obtained with this panel, expression of other antigens was evaluated, 
including CD3, CD4, CD8, CD11b, CD14, CD18, CD20, CD25, CD44, CD79a, CD117 and 
major histocompatibility class (MHC) II. 
All antibodies were previously titered to define correct working dilutions. For surface 
marker labelling, 50 µl cell suspensions, adjusted at 5 x 105 cells/tubes were incubated 
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for 20 min at 4-8°C with 50 µl primary antibody and 25 µl of RPMI 1640 medium plus  
5%  fetal  bovine  serum  (FBS)  plus  0.2%  sodium  azide.  After  incubation  cells  were 
washed and then resuspended in 500 µl PBS. If directly labelled primary antibodies 
were not available, 50 µl 1:400 FITC-conjugated rabbit anti-mouse IgG (Serotec, oxford, 
UK)  or  3  µl  of  pure  FITC-conjugated  Goat  anti-mouse Ig  (BD  Bioscience,  USA)  was 
added.  After  another  20  min  incubation  at  4-8°C,  the  cells  were  washed  and 
resuspended in 500 µl of PBS.
For CD79a intracellular staining, cells were previously labeled with an anti-CD45-FITC, 
and then washed and permeabilized using BD FACS permeabilizing solution 2 (Becton 
Dickinson,  San  Jose`,  CA).  After  washing,  cells  were  incubated  with  anti-CD79a  PE 
conjugated antibody,  then washed and resuspended in 500 µl  PBS.  As a control,  a 
separate  aliquot  was  submitted  for  permeabilization  and  an  appropriate  isotype-
matched negative  control  was  added in  order  to  distinguish  between specific  and 
nonspecific labeling.
The antibody panel used to stage lymphoma on PB and BM samples varied based on 
the phenotype of neoplastic cells identified in the LN sample. If the LN sample was not 
adequate for FC, the basic antibody panel was applied to PB and BM, with the addition 
of CD4 and CD8. Specificity, sources and clones of antibodies are listed b in Fig. 8:
Figure  8:  Antibodies  used  for  the  flow  cytometric  immunophenotyping  of  samples  enrolled  in  the 
present study (Novacco et al., 2015)
Samples were acquired using a flow cytometer (FACScalibur, Becton Dickinson) and 
analysed using Cell Quest software (Becton Dickinson). A minimum of 5,000 events for 
LN and 10,000 events for PB and BM were gated to exclude dead cells. Neoplastic cells 
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were identified on the morphologic scatter cytogram or on CD45 versus FSC cytogram. 
For high-grade lymphomas or acute leukemias neoplastic cells were easily identified 
because  of  high  FSC  or  CD45  expression.  For  low-grade  lymphomas  or  chronic 
leukemias  cellular  scatter  characteristics  were  not  always  enough  to  differentiate 
neoplastic from residual cells, thus neoplastic populations were identified according to 
a  combination  of  scatter  and immunophenotypic  features  (such  as  antigen  under-
expression or unusual phenotype). The percentage of neoplastic cells and mean FSC 
(evaluating mean cellular size) were evaluated on non-permeabilized samples. Residual 
non-neoplastic cells of the same lineage and residual non-neoplastic cells of another 
lineage  (for  instance  B  lymphocytes  for  T-cell  markers)  were  used as  positive  and 
negative internal controls, respectively.
Criteria for diagnosis
The final diagnosis was based on a comprehensive evaluation of all the data provided 
by the referring veterinarian, including different combinations of history, presenting 
complaint, clinical signs, cytological smear, haematology data, LN/PB/BM FC analysis. 
Cases  included  in  the  present  study  were  classified  based  only  on  the  FC  report, 
without any re-evaluation of the raw FC data. 
Samples were considered to be ‘non-diagnostic’ if one or more of the following criteria 
were present: (1) insufficient cellularity (< 1 x106 cells in total); (2) sample composed 
primarily  of  dead  cells;  and  (3)  if  flow  cytometric  results  strongly  differed  from 
cytological  evaluation,  for  example,  when  neoplastic  cells  were  distrupted  during 
processing and only a small residual non-neoplastic population was labelled. Dead cells 
were identified by  gross  evaluation  of  the sample  (based  on  colour,  odour  or  the 
presence of tissue debris) and/or with a viability stain (propidium iodide), which was 
included in 2013 in the antibody panel. Sample was considered adequate if >50% of 
cells was propidium negative.
Samples  were  considered  to  be  ‘negative  for  lymphoid  tumour’  if:  (1)  a  mixed 
population  of  predominantly  small  cells  was  present  with  a  cytology  supporting  a 
reactive/hyperplastic  lymph  node;  or  (2)  other  causes  of  lymphadenomegaly  were 
identified by immunophenotyping and cytology, for example, LN metastasis from solid 
tumours, histiocytic tumours and plasma cell  tumours. Samples were considered as 
‘likely lymphoid tumour’ if: (1) flow cytometry from a lymph node showed a prevalent 
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population (> 65%) of lymphoid cells with a single phenotype, but only a reduced panel  
of  antibodies  was  allowed  and/or  the  lack  of  a  good  quality  cytological  smear 
precluded a definitive diagnosis;  (2) flow cytometry from a lymph node was poorly 
cellular (< 1  x 106 cells in total) or provided equivocal results, but LN cytology was 
highly  suggestive  of  lymphoma  and  immunophenotyping  of  PB  and/or  BM  was 
suggestive  of  a  lymphoid  tumour.  Cases  were  classified  as  ‘lymphoid  tumour’  if  a 
definitive  diagnosis  of  lymphoma or  leukaemia  was  made  based on  the  results  of 
immunophenotyping of LN, PB, or BM. In many cases, extended subtyping of lymphoid 
neoplasia  was  possible  based  on  immunophenotyping  of  different  tissues  and 
cytological evaluation: (1) B cell lymphoma, irrespectively of the grade; (2) high grade T 
cell lymphoma, based on immunoreactivity to T cell markers and cytological aspects 
including high numbers of mitotic figures (≥5 mitotic figure/5 high power field (HPF) 
(×40) (Fournel-Fleury et al., 1997); (3) low grade T cell lymphoma, based on typical T  
zone pattern staining on FC and/or distinctive cytological features (4) acute leukaemia, 
starting  with  PB  or  BM  immunophenotyping  of  precursor  cells  confirmed  by  LN 
infiltration  and  (5)  chronic  lymphocytic  leukaemia,  starting  with  PB  or  BM 
immunophenotyping confirmed by LN infiltration.
Data collection and  statistical analysis 
Statistical analysis was applied to identify pre-analytical variables possibly affecting the 
likelihood  to  reach  a  diagnosis;  for  this  purpose,  samples  were  grouped  into 
‘diagnostic’ (if any diagnosis had been made, regardless of the level of confidence) and 
‘non-diagnostic’  (including  samples  not  adequate  for  processing  and  samples 
processed but not diagnostic). 
Pre-analytical  variables  investigated  were related to:  (1)  animal  variables,  including 
breed (pure or mixed), age (years), sex (female, spayed female, male, neutered male) 
and  size  (toy/small,  medium,  large/giant);  (2)  sampling  and  shipping  variables, 
including year (2009–2015), season (cool to cold from October to March, warm to hot 
from April  to September),  referring veterinarian (veterinarians who sent > 10 cases 
over the study period were considered individually, while veterinarians sending less 
than 10 cases in total were grouped in a single category), origin and shipping (‘within 
institution’, ‘out of institution hand-delivered’, ‘out of institution delivered by express 
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courier’); and (3) sample variables, including type of sample (LN alone, LN plus PB, LN  
plus  PB  and  BM,  LN  plus  BM),  LN  cytological  smear  (present  or  not),  cellular 
concentration of the LN sample and presence of gross artefacts (haemodilution, dead 
cells, none). Univariate and multivariate binomial logistic regressions were performed 
using  SPSS  v20.0  for  Windows  (IBM).  Multivariate  analysis  was  performed  with  a 
backward step selection, including only variables with P < 0.3 at univariate analysis.  
Significance was set at P<0.05.
Results
Out of 1273 samples, 264 cases were excluded due to lack of information regarding 
the sample (n = 88; 6.9%) or due to sampling of tissues other than LN (n = 176; 13.8%).  
Among the latter, 59 (33.5%) cases were represented by PB and BM, 49 (27.8%) cases  
by PB alone, 28 (15.9%) cases by extranodal masses (other than cutaneous), 18 (10.2%) 
cases  by  effusions,  nine  (5.1%)  cases  by  spleen,  seven  (4.0%)  cases  by  cutaneous 
masses,  two  (1.1%)  cases  by  liver,  and  four  (2.3%)  cases  by  other  tissues.  The 
distribution of tissue type including samples excluded is shown in fig. 9.
Twenty-two cases (1.73%) were excluded because the final report was not available. 
Finally,  987 cases fulfilled the inclusion criteria  and were included in the statistical 
analysis. Seventy-two (7.3%) samples were non-diagnostic. Among the 915 diagnostic 
FNAs, 839 (91.7%) were ‘conclusive for lymphoid tumour’, 61 (6.7%) were ‘negative for 
lymphoid tumour’, and 15 (1.6%) were ‘likely lymphoid tumour’. A specific diagnosis 
was available for 812 cases; 596 (73.4%) cases were B cell lymphomas, 143 (17.6%) 
cases  were  high  grade  T  cell  lymphomas,  60  (7.4%)  cases  were  low  grade  T  cell  
lymphomas,  eight  (1.0%) cases  were acute leukaemias,  and five (0.6%) cases were 
chronic lymphocytic leukaemias. The results of univariate and multivariate analyses, 
and the odd ratios for diagnostic samples, are summarised in Table 1.
Animal-related variables 
Breed was reported in 911 cases; there were 239 (26.2%) mixed breed dogs. Among 
the remaining 672 dogs, the most prevalent breeds included German shepherd (n = 59; 
8.8%), Boxer (n = 56; 8.3%), Golden retriever (n = 46; 6.8%), Labrador retriever (n = 44; 
6.5%), Rottweiler (n = 38; 5.7%) Doberman pinscher (n = 37; 5.5%), Beagle (n = 29;  
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4.3%),  Bernese  mountain  dog  (n  =  23;  3.4%),  English  bulldog  (n  =  21;  3.1%)   and 
Yorkshire terrier  (n = 21; 3.1%).
Table 1: results of univariate and multivariate analysis for different pre-analytical variables examined for  
their effect on flow cytometric analysis of samples from dogs with clinically suspected lymphoma. 
Odds ratio for the probability to provide a diagnostic result are also given. LN, lymph node; PB, 
peripheral blood; BM, bone marrow; Ref, reference; ND, not detectable. * P < 0.05. 
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Figure 9: type of tissues received for immunophenotyping from 2009 to 2015.
 Many other breeds were represented, with less than 20 cases each. In 76 cases, the 
breed  was  not  recorded.  Since  the  size  of  mixed  breed  dogs  generally  was  not 
available, this variable was analysed only within the purebred dog group. Among the 
latter, 415 (61.8%) were of large/giant size, 115 (17.1%) were medium-sized and 142 
(21.1%) were of toy/small size. Sex was reported in 901 cases; there were 213 (23.6%) 
intact females, 210 (23.3%) spayed females, 397 (44.1%) intact males and 81 (9.0%)  
castrated males. The male/female ratio was 1.15:1. Age was known for 899 dogs; the 
median age was 8 years (mean 8.4 ±  3.2 years, range 1-17 years). None of the patient-
related variables significantly influenced the likelihood of having a diagnostic sample. 
Variables related to sampling and shipping 
The number of cases per year steadily increased during the study period, ranging from 
63 cases fulfilling the inclusion criteria  in 2009 to 200 cases in 2015 (Fig.  10).  The 
highest percentage of diagnostic cases was reached in 2012 (124/128 cases, 96.9%) 
and the lowest in 2015 (174/ 200 cases, 87.0%). The likelihood of having a diagnostic  
sample varied significantly by years both with univariate (P = 0.031) and multivariate (P 
= 0.016) analyses. The percentage of samples collected in the cold and hot seasons was 
almost similar (51.2% and 48.8%, respectively) without any significant difference (P = 
0.15).  Thirteen  veterinarians  sent  >  10  samples,  ranging  from 13  to  207  samples; 
veterinarians sending < 10 samples were grouped together (363 cases, 36.8%). Most of  
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the samples for which this information was available had been sent to the laboratory 
by express courier (559/816, 68.5%), 159 (19.5%) were sampled outside the institution 
and hand-delivered, and 98 (9.9%) were sampled within the institution. The likelihood 
of a having a diagnostic sample was not influenced by these variables on univariate 
analysis.  However,  the proportion  of  diagnostic  samples  varied  significantly  among 
veterinarians based on multivariate analysis (P = 0.004). 
Figure 10: per-year distribution of the number of cases included in the present study.
Variables related to sample material 
In the majority of cases (572; 58.0%), samples from all three sites (LN, PB and BM) of  
the same dog were available; LN and PB were sent in 225 (22.8%) cases, LN alone was 
submitted in 163 (16.5%) cases, and LN and BM were submitted in 27 (2.7%) cases. 
Sample material  significantly influenced the likelihood of obtaining a diagnosis  (P =  
0.025). In particular, cases for which both LN and PB, or all three sites (LN, PB and BM) 
were obtained, had a higher likelihood of being diagnostic, compared to samples from 
LN alone (P = 0.011 and P = 0.006, respectively).  The type of sample  material  also 
significantly  influenced the  likelihood  of  having  diagnostic  samples  on  multivariate 
analysis (P = 0.031). A LN cytological smear was provided in 634/987 (64.2%) cases, but 
the quality of these smears was not assessed in the present study. The presence of a 
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cytological smear significantly improved the likelihood of having a diagnostic sample (P 
= 0.009) only on univariate analysis. Lymph node sample cellularity was highly variable 
among cases, ranging from 0.02 to  436.19 x 109 cells/L (median 12.44 x 109 cells/L, 
mean  29.21-48.13  x  109 cells/L).  Lymph  node  sample  cellularity  did  not  affect  the 
likelihood of having diagnostic samples based on univariate analysis (P = 0.104), but 
was statistically significant on multivariate analysis (P = 0.013), with cellularity being 
higher in diagnostic than in non-diagnostic samples (median 13.1 x 109 cells/L and 2.09 
x 109  cells/L,  respectively).  In the group of non-diagnostic  cases, the cellularity was 
lower than the minimum adequate concentration (5.0 x 109/L) in 52.8% of cases, and 
lower than the lower cut-off value generally considered to be suitable for analysis (1.0  
x 109/L) in 37.5% of cases. These percentages were much higher than those found in 
diagnostic samples (21.0% and 3.4%, respectively).
Artefacts  were  reported  in  nine  non-diagnostic  samples  (12.5%),  including  one 
haemodiluted sample and eight necrotic samples, and in 18 diagnostic samples (2.0%), 
including three haemodiluted and 15 necrotic samples. Haemodilution did not affect 
the likelihood of having a diagnostic sample. On the contrary, necrotic samples were 
significantly less likely to be diagnostic on both univariate and multivariate analysis (P < 
0.001 for both analyses).
Discussion
The results of the present study indicate that FC can be a suitable ancillary diagnostic  
aid in cases with a tentative diagnosis of canine lymphoma, since it provided diagnostic  
results  in  the  majority  of  cases  (about  90%).  Among  the  pre-analytical  variables 
investigated, no association was identified between signalment and the likelihood of 
obtaining a diagnostic result.  In particular, dog size and breed did not influence the 
odds of obtaining a diagnosis. Fine needle aspiration of a lymph node is usually carried  
out without sedation, and, in theory, obtaining a good quality  fine needle aspirate is 
more difficult in small-sized or aggressive dogs. However, the results of the present 
study indicate that FNA provides good quality s 
The  likelihood  of  obtaining  a  diagnosis  varied  among  submitting 
veterinarians/institutions, possibly reflecting different technical skills of the operator 
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(veterinarian), supporting the necessity of an adequate technical training to increase 
the likelihood of obtaining a diagnostic result.
Regarding  the  method  of  delivery,  no  differences  were  found  among  samples 
submitted from the internal oncology service of the University of Milan, which were 
delivered within few minutes following sampling, those delivered in person within a 
few hours  following sample collection and those shipped using an express courier. 
Moreover, no differences were found between samples shipped during the cold and 
hot seasons. The standard requirements of our laboratory include a maximum shipping 
time of 24 h and shipment on ice packs for FC samples. Therefore, our results are only 
valid under these conditions. In human medicine, refrigeration of FC samples generally 
is not recommended, since some antigens may be internalised and this may bias the 
final  results  (Ekong et al.,  1993).  Studies  on this  aspect in  veterinary medicine are 
currently lacking, but it seems reasonable to refrigerate the samples during shipment 
to prevent cell disruption due to high temperatures, mainly in the hot season and in 
hot countries. It is currently unknown whether canine antigens vary their expression 
following refrigeration. 
Several studies have been conducted on human samples using fixative solutions for 
stabilizing cells (Saxton and Pockley, 1998 ; Warrino et al., 2005; Davis et al., 2011); on 
the authors knowledge, one similar  study has been performed on fixed samples of 
canine blood, showing that cells stored at room temperature were easily identifiable 
on both cell counter and cytometer up to 7 days, and marker expression was stable up 
to 3 days (Cian et al., 2014). However, the study was conducted on healthy dogs, thus 
currently there is  no information in literature regarding the stability of   neoplastic  
lymphoid cells. 
Sample type and sample characteristics had the greatest influence on the diagnostic 
power of FC. The major factor leading to a non-diagnostic result was poor cellularity, 
with more than a half of non-diagnostic samples having a cell concentration lower than 
recommended,  while  haemodilution  and  dead  cells  have  minimal  effects  on  FC 
analysis. When a gross haemodiluition was evident, erithrocytes were removed within 
a rapid lysis step, while necrotic debris when present, may be easily identified by gross 
evaluation (based on colour, odour or the presence of tissue debris) or using a viability 
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stain, such as propidium iodide. Thus, artefacts, such as haemodilution and dead cells, 
made a minor contribution to non-diagnostic samples.
Having  sample  material  from  different  sites  (LN,  PB,  BM)  and  a  concurrent  LN 
cytological  smear  available  improved  the  likelihood  of  establishing  a  diagnosis  of 
lymphoid neoplasia. Therefore, complete cases, including FNA from LN, PB and BM, 
with  cytology  smears  prepared  before  submission,  are  desirable  for  a  more 
comprehensive evaluation by a clinical pathologist.  Specifically, cytological evaluation 
of a smear may help to differentiate reactive/hyperplastic lymph nodes from lymphoid 
tumours in which the neoplastic population, which tends to be more fragile, has been 
disrupted. In the first case, samples would be classified as ‘diagnostic, non-neoplastic’; 
in the second case, they would be classified as ‘non-diagnostic’. 
The  presence  of  neoplastic  cells  detected  via  flow  cytometry  in  PB  and/or  BM, 
together with a LN cytology compatible with lymphoma, may also permit a putative 
diagnosis of ‘likely lymphoma’, even if LN sample cellularity is too low for FC. This could 
be achieved when neoplastic cells can be differentiated from non-neoplastic cells, for 
example when the cells showed an aberrant phenotype (such as a T zone pattern) or  
when a high percentage of large CD21+ cells were detected. 
Evaluation of PB and/or BM would also be important for differentiation of acute and 
chronic  lymphoid  leukaemias  with  secondary  lymph  node  infiltration  from  nodal 
lymphoma with a haematogenous phase. The results of our study suggest that, when 
LN cellularity was too low to perform FC, flow cytometry of PB was most likely to be 
diagnostic. Our results indicate also that having a BM aspirate available for FC did not  
increase the likelihood of having a diagnostic sample if LN and PB were also submitted. 
This  suggests  that  submitting  peripheral  blood  together  with  a  LN  aspirate  will 
facilitate interpretation of FC results and will assist with staging of lymphoma. 
The limits of this study are inherent to its retrospective nature. Some possible sources 
of biases were not analysed, including the localization and size of the LN sampled, the 
technique used for sampling (free hand vs. ultra-sound guided, suction vs. capillary 
technique), the use of different transport media (RPMI vs. phosphate buffered saline 
vs. saline solution) and the quality of the cytological smears. Another limitation is the 
lack of a gold standard for the final diagnosis, which precluded us from defining the 
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diagnostic performances of both cytology and FC. This should be addressed in a future, 
prospective study.
In conclusion, flow cytometry performed on canine LN FNA specimens is a suitable 
diagnostic  tool  to confirm lymphoma in the majority of cases, regardless of animal 
characteristics, provided that the sample has sufficiently high cellularity, is submitted 
within 24 h following sampling and is shipped on ice packs. Packaging and shipping 
should be standardised to assure fast delivery within 24 h of sampling. Haemodilution 
has minimal effects on FC analysis, but veterinarians should make any possible effort  
to obtain a highly cellular sample. The addition of a PB sample and a LN cytological  
smear can be recommended to improve the likelihood of receiving a conclusive result. 
The results of the present study were used for a degree thesis (FATTORI PREANALITICI 
CHE INFLUENZANO LA DIAGNOSI  CITOFLUORIMETRICA DI  LINFOMA NEL CANE)  and 
then published on a peer review international journal (Comazzi S, Cozzi M, Bernardi S, 
Zanella DR, Aresu L, Stefanello D, Marconato L, Martini V. EFFECTS OF PRE-ANALYTICAL 
VARIABLES  ON  FLOW  CYTOMETRIC  DIAGNOSIS  OF  CANINE  LYMPHOMA:  A 
RETROSPECTIVE STUDY (2009-2015). Vet J 2018 Feb;232:65-69.) 
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3.2  CANINE  SMALL  CLEAR  CELL/T-ZONE  LYMPHOMA: CLINICAL  AND 
PATHOLOGICAL CHARACHTERIZATION
Background
Small clear cell/T-zone lymphoma (TZL) represents a very peculiar canine lymphoma 
without a human counterpart and is identified as a single entity characterized by a 
small clear cell appearance by cytology (Fournel-Fleury et al., 2002), a nodular pattern 
of expansion from cells derived from the paracortex by histology (Valli et al., 2006) and 
a  peculiar  immunophenotype  staining  negative  for  CD45  by  flow  cytometry  (FC), 
frequently associated with an aberrant CD21 expression (Martini et al., 2013; Seelig et 
al., 2014). In spite of the relative frequency of this tumor subtype, representing about 
3-17 % of all canine lymphomas (Gelain et al., 2008; Ponce et al.,  2010; Valli et al.,  
2011; Aresu et al., 2015) to date, the clinical presentation and characteristics of dogs 
with this lymphoma subtype have only been summarily described, reporting indolent 
nature with a long survival (Flood-Knapik et al., 2013; Ponce et al., 2004; Seelig et al.,  
2014). 
CD45-negative hematopoietic neoplasms other than canine TZL have been reported 
both in humans (Ozdemirli et al., 1996; Ratei et al., 1998; Kumar et al., 2005; Wang et  
al.,  2015) and dogs (Gelain et al.,  2008; Williams et al.,  2008),  but the mechanisms 
underlying  this  phenotypic  aberrancy  have  not  been  investigated.  CD45  is  a 
transmembrane protein tyrosine phosphatase expressed by the leukocytes surface in 
many different species, including dog. Two major CD45 isoforms (CD45RA and CD45R0) 
have  been  described  in  dog  and  expression  patterns  are  different  depending  on 
leukocytes subclasses and activation status (Goto-Koshino et al., 2014). 
The aim of the present study was to characterize TZL from a clinical and pathological 
point of view and to try to investigate some possible pathogenetic aspects.  To the aim, 
the present work has been organized in two different tasks. The first purpose was to 
describe  the  clinical  presentation  and  outcome in  a  retrospective  series  of  canine 
CD45-negative small clear cell/TZL; the second purpose was to confirm the absence of 
CD45 at the protein level in a group of dogs with TZL, via the concomitant use of FC 
and immunohistochemistry, and to investigate the possible origin of CD45 protein loss, 
whether associated to genetic or transcriptional  or post-translational  modifications. 
Based on the absence of CD45 protein in canine TZL, subsequently the amount of CD45 
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transcript and the presence of CD45 gene will be investigated in the same cohort of  
dogs. For the purpose of the study a control group composed by normal sorted T cells, 
high grade T-cell lymphomas and normal lymph nodes has been selected. 
Canine TZL: clinical presentation and outcome in a retrospective case series
Material and Methods
Case selection
The  FC  databases  of  the  flow  cytometric  diagnostic  services  of  Department  of 
Veterinary Medicine (University of Milan, Milan, Italy) and Department of Veterinary 
Sciences (University of Turin, Grugliasco, Turin, Italy) were interrogated from January 
2009  to  December  2014,  and  the  CD45-negative,  small  (FSC-height  <400)  T-cell 
lymphoma  cases  were  selected.  Additional  inclusion  criteria  were  a  cytological  
diagnosis  of  small  clear  cell  lymphoma  (Fig.  11)  and  when  available  a  confirmed 
histopathological diagnosis of TZL (Fournel-Fleury 2002; Valli et al., 2006) .
Figure 11: cytological smear of a TZL,  carachterized by  small lymphoid cells with clear cytoplasm and 
frequent ‘hand-mirror’ shape (small-clear cell appearance).
Flow cytometric immunophenotyping on LN was performed as previously described 
(first study of the thesis). If available, PB and BM were also examined via FC to quantify 
infiltration. Samples were acquired either with a FACScalibur or with a BD Accuri C6 
(Becton  Dickinson,  San  Josè,  CA,  USA)  and  analysed  using  the  specific  software 
CellQuest Pro or CFlow Plus (Becton Dickinson). PB and BM samples were considered 
infiltrated if a distinct CD45-negative population with similar phenotype shown in the 
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LN was detected. Infiltration was then quantified as the percentage of neoplastic cells 
out  of  the  total  events  acquired,  after  exclusion  of  debris  and platelets  based on 
morphological scattergrams.
The neoplastic phenotype, PB and BM infiltration degree were recorded for each case. 
Clinical  data  were  obtained  from  the  medical  records  and  by  phone  calls  to  the 
referring  veterinarians.  Background  information  collected  for  each  dog  included 
signalment, presence or absence of clinical symptoms, complete blood count (CBC) at 
diagnosis, treatment (if any), date and cause of death. Haematological abnormalities 
were defined as values out of the laboratory reference interval (RI).
Clinical stage was based on the World Health Organization (WHO) criteria for canine 
lymphoma; however, splenic, liver, PB and BM aspirates were not routinely performed 
and therefore it was not possible to definitively differentiate stage III from stage IV 
disease in some cases. 
Median survival time was calculated via SPSS v17.0 for Windows. Survival time was 
defined as  time between diagnosis  and death.  Dogs  that  died or  were euthanized 
because  of  lymphoma  were  recorded  as  events;  dogs  lost  to  follow  up,  dead  for 
unrelated causes or still alive at data analysis closure were censored. Because of the 
wide range of treatment protocols, prognostic factors were not investigated.
Results
Clinical presentation
51 dogs met the inclusion criteria. Cytology confirmed a small clear cell appearance in 
all  cases,  whereas  histopathology  confirmed  TZL  in  the  8  cases  also  undergoing 
lymphadenectomy. Breed
was reported for 43 dogs, including 33 (76.7%) pure breed dogs and 10 (23.3%) mixed-
breed dogs.  The most represented breeds were Boxer (n=5),  English bulldog (n=3), 
Labrador  retriever (n=3)  and Shih tzu (n=3).  Sex was reported for  47 dogs.  Among 
these, 23 (48.9%) were male (2 neutered) and 24 (51.1%) were female (12 spayed).
Age was reported for 44 dogs. Overall mean age was 9.9 ± 2.3 years (median 10 years; 
range, 5–14 years). In particular, 18 (40.9%) dogs were <10 years old and 26 (59.1%) 
were ≥10 years old. CBC data were available for 44 dogs. Four (9.1%) dogs had a mild 
anaemia, 3 (7.3%) had thrombocytopenia, 2 (4.5%) had leukopenia and 17 (38.6%) had 
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leukocytosis,  4  (9.1%)  had  neutropenia  and  8  (18.2%)  had  mature  neutrophilia,  2 
(4.5%) had lymphopenia and 28 (63.6%) had lymphocytosis.
Overall mean white blood cell (WBC) count was 17.59 ± 10.52 × 103/μL (median 14.39 
× 103/μL; range, 0.8–45.72 × 103/μL); overall mean neutrophil count was 8.24 ± 5.44 × 
103/μL (median 6.73  ×  103/μL; range, 0.59–27.2  ×  103/μL); overall mean lymphocyte 
count was 8.31 ± 6.61 × 103/μL (median 6.95 × 103/μL; range, 0.12–30.76 × 103/μL). In 
20 (39.2%) cases, neoplastic cells were CD8+, in 17 (33.3%) cases cells were CD4–CD8 
double  negative,  in  8  (15.7%)  cases  cells  were  CD4+,  in  4  (7.8%)  cases  cells  were 
CD4+CD8+ double positive
and  in  2  (3.9%)  cases  two  distinct  CD45-negative  populations  were  identifiable, 
staining  positive  for  CD4  and  CD8,  respectively.  Forty-two  (82.4%)  cases  stained 
positive for CD21.
Stage was reported for 43 dogs; however, staging procedures largely varied among 
veterinarians and were not standardized. One (2.3%) dog had stage I disease, 1 (2.3%) 
dog had stage III disease, 1 (2.3%) dog had stage IV disease and 40 (93%) dogs were 
classified as stage V because of PB and/or BM flow cytometric infiltration; in addition, 
skin and lungs were presumed to be involved in one case each.
The dog with skin involvement presented multifocal itchy alopecia of abdomen, neck 
and pinnae; histopathological examination of cutaneous biopsies from the neck and 
the abdomen revealed a diffuse subepidermal infiltration by small lymphocytes. Lung 
involvement was diagnosed based on thoracic radiographs, that revealed a generalized 
multifocal interstitial structured pulmonary pattern, and cytological examination of a 
percutaneous  fine  needle  aspiration,  that  was  suggestive  of  round  cell  tumour, 
whereas bronchoalveolar lavage was negative for lymphomatous cells.
Substage  was reported for  22 dogs.  Among  these,  18 (81.8%)  were  asymptomatic  
(substage  a),  whereas  4  (18.2%)  had  clinical  signs  (substage  b),  mainly  dyspnoea 
because of enlarged submandibular LNs. PB and BM samples were analysed via FC in 
40 and 12 dogs, respectively, and all of them proved to be infiltrated. Overall mean PB 
infiltration was 34.6±  17.53% (median 35.07%; range,0.93–64.6%). Overall mean BM 
infiltration was 6.85± 7.88% (median 2.15%; range, 0.5–24.1%).
In the 12 cases that had BM analysed, mean PB infiltration was 24.64± 14.41% (median 
27.1%; range, 1.8–41.65%); in particular, PB infiltration was higher than BM in all cases 
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but one. Flow cytometric scattergrams of LN, PB and BM from one representative case 
are shown in Fig. 12. 
Clinical presentation is reported in Table 2.
Outcome
Follow-up  data  were  available  for  26  dogs.  Four  dogs  received  no  therapy  after 
diagnosis, 3 received corticosteroids alone and the remaining 19 dogs were treated 
with  different  protocols,  including  dose-intense  (n=12)  and  metronomic  (n=7) 
chemotherapy.
Overall median survival was 760 days (range, 15–1150 days). Eight of the 26 dogs died 
of lymphoma during the study period, with a median survival of 180 days (range, 15–
760 days); among them, 3 dogs (37.5%) died within 3 months from the diagnosis, and 5 
(62.5%) survived longer than 6 months. Among the remaining 18 dogs, 2 were lost to 
follow up after  120  and 386  days,  respectively,  5  dogs  died  because  of  unrelated 
causes and 11 were still alive at data analysis closure, with a median follow-up time of 
335 days (range, 50–1150).
Interestingly, three dogs (12%) developed a second malignancy during the study period 
(glioma,  melanoma and oral  carcinoma):  two of  them died because of  the second 
malignancy, whereas the dog with oral carcinoma was still alive at the end of the study 
after 1150 days from the diagnosis.
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Figure 12: flow cytometric scattergrams representing lymph node aspirate (A and B), peripheral blood (C  
and D) and bone marrow (E and F) from a dog with small  clear cell/T-zone lymphoma. Events were  
displayed at first based on morphological properties (A, C and E) and a gate (R1) was set to exclude  
platelets and debris.  R1 cells  were then displayed based on CD5-fitc and CD45-apc fluorescence.  A  
distinct CD45-negative and CD5-positive population was identified in all samples (B, D, F, lower right  
quadrant), accounting for 98.6, 12.2 and 0.95% of all cells in the lymph node, peripheral blood and bone 
marrow, respectively. 
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Loss of CD45 cell surface expression in canine T-zone lymphoma results from reduced 
gene expression
Materials and methods
Case selection
Samples from the present study were collected from the flow cytometric diagnostic 
services of Department of Veterinary Medicine (University of Milan, Milan, Italy) and 
Department  of  Veterinary  Sciences  (University  of  Turin,  Grugliasco,  Turin,  Italy).  
Consecutive cases with a final diagnosis of TZL based on cytological appearance and FC 
immunophenotype  (Martini  et  al.,  2013)  were  included.  In  addition,  cases  of  non-
neoplastic lymph node and of high grade T-cell lymphoma showing CD45 expression 
were  included as  controls.  When  available,  histopathological  sections  of  the  same 
cases were considered to confirm the diagnosis  and perform immunohistochemical 
analyses.
Cell sorting
Neoplastic cells (CD45-negative and CD5-positive) from a subset of TZLs and normal T-
cells (CD45-positive and CD5-positive) from non-neoplastic lymph nodes were sorted 
using a fluorescence-activated cell sorter (BD FACSVantage, BD Biosciences, San Josè, 
CA,  USA).  A  minimum  sorting  yield  of  1  ×105 with  more  than  95%  purity  was 
considered suitable for quantitative real-time PCR analysis.
Histopathology and immunohistochemistry
For histological examination, three  μm sections were stained with haematoxylin and 
eosin (HE).
For  lymphoma  phenotyping,  a  panel  of  primary  antibodies  was  applied  including: 
monoclonal  mouse anti-human CD3 (Clone F7.2.38,  Dako,  Atlanta,  Georgia,  USA,  T 
cells;  diluted 1:100),  monoclonal mouse antihuman CD5 (Clone CD5/54/F6, Dako, T 
cells; diluted 1:100), monoclonal mouse anti-human CD79acy (Clone HM57, Dako, all 
stages of B cells; diluted 1:100) and CD20 epitope-specific rabbit antibody (RB-9013-P, 
Thermo  Fisher  Scientific  Inc.,  Cheshire,  UK;  mature  B  cells;  diluted  1:800). 
Immunohistochemical  analysis  for  CD45 was performed using an anti-canine CD45, 
clone CA12.10C12 (Leukocyte Antigen Biology Laboratory,  UCDavis,  Davis,  CA,  USA) 
(dilution 1:100).
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Antibody was detected using an avidine-biotine-peroxidase complex technique with 
the Vectastain Elite ABC Kit (Vector Laboratories Inc., Burlingame, California, USA). For 
negative  controls,  the  primary  antibody  was  excluded  during  the  process. 
Membranous immunolabelling of the antibodies was evaluated in neoplastic cells in 
lymphomas  and  in  the  control  lymph  nodes.  Evaluation  consisted  of  qualitative 
assessment of cell types and location.
Quantitative real-time RT-PCR for CD45 transcript
The transcript analysis was performed on lymph node aspirates and on normal sorted 
T lymphocytes, diluted in RNAlater® (Applied Biosystems, Life Technologies, Carlsbad, 
CA) and stored at −20 °C until processing. The total RNA was isolated from cell pellets 
using  the  RNeasy  Mini  Kit  (Qiagen,  Milan,  Italy)  according  to  the  manufacturer’s 
instructions. To avoid genomic DNA contamination, on-column DNase digestion with 
the RNase-Free DNase (Qiagen) set was performed. First-strand cDNA was synthesised 
from  100  ng  of  total  RNA  using  High  Capacity  cDNA  Reverse  Transcription  Kit 
(Invitrogen, Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol. 
The generated cDNA was used as template for quantitative real-time RT-PCR (qRT-PCR) 
in a LightCycler 480 Instrument (Roche Diagnostics, Basel, Switzerland) using standard 
PCR  conditions.  The  primers  were  designed  using  Primer  Express  2.0  (Applied 
Biosystem,  Life  Technologies,  Carlsbad,  CA).  Canine  CD45  was  amplified  using  the 
primer pair 5′- ATG GAG ATG CAG GGT CAA AT-3′ (forward) and 5′-GCA ATG TAT TTC 
CTG GGT TCT T-3′ (reverse). Primer pairs were designed on exon 19 and 20, shared by 
the two CD45 variants. In addition, these exons spare an intronic region of>3800 bp 
thus excluding the amplification of contaminant genomic DNA. Calibration curves using 
a 7-fold serial dilution (1:2) of a cDNA pool revealed PCR efficiencies of 99.5%. Canine 
transmembrane BAX inhibitor motif containing 4 (CGI-119) was chosen as reference 
gene for the absence of pathological state dependent differences in mRNA expression, 
as reported by Aricò et al. (2013). ΔΔCt method (Livak and Schmittgen, 2001) was used 
for the relative quantification of mRNA, ultimately expressed as Relative Expression 
(RE).
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Quantitative real-time PCR for CD45 DNA
Lymph node aspirates and CD45-negative/CD5-positive cells  sorted from TZLs  were 
stored at  −20°C until processing for DNA load analysis. Genomic DNA was extracted 
from  cell  pellets  using  DNeasy®  Blood  &  Tissue  kit  (Qiagen)  following  the 
manufacturer’s  instructions.  Specific  primers  for  CD45  were  designed  using 
Primer3web  (primer3.ut.ee)  as  follows:  primer  pair  CD45  5′-
AGCAAAGACACACGAAAGCC-3′  (forward)  and  5′-GCAATGTATTTCCTGGGTTCT  −3′ 
(reverse)  for  the amplification of  a  fragment of  257 base pairs.  In  order to detect  
reference genes for normalization of samples, primers targeting canine CGI-119 and 
canine  GAPDH  was  designed  as  described:  primer  pair  CGI-119  5′-
GGATTTTGTGCTTGTCAGGAA-3′  (forward)  and  5′-CACTGGGAGCTTAGCAATTACA-3′ 
(reverse) for the amplification of a fragment of 279 base pairs; primer pairs GAPDH 5′-
GGAGAAAGCTGCCAAATATG-3′  (forward)  and  5′-ACCAGGAAATGAGCTTGACA-3′ 
(reverse) for the amplification of a fragment of 194 base pairs (Mortarino et al., 2009). 
In order to evaluate the PCR efficiency using a relative standard curve, dilution series 
were prepared by performing four fold serial dilution (1:10) of a control sample.
Efficiency was 100.47% for CD45,  102.16% for CGI119 and 98.70 for  GAPDH.  ΔΔCt 
method (Livak and Schmittgen, 2001) was used to describe the CD45 DNA load to the 
reference genes, expressed as Relative Quantification (RQ).
Amplicon sequencing
The  specificity  of  the  amplification  for  CD45  transcript  and  DNA  was  checked 
sequencing  the  DNA  amplicon  by  Sanger  chemistry  (Eurofins  Genomics  S.r.l.,  
Vimodrone, MI, Italy). The obtained sequences were aligned with the expected target 
sequence using BLAST (https://blast.ncbi.nlm.nih.gov).
Statistical analysis
All  analyses  were  performed  with  standard  statistical  software  (SPSS  v20.0  for 
Windows)  and  significance  was  set  at  p≤  0.05  for  all  tests.  Data  distribution  was 
assessed  via  Shapiro-Wilk  test  for  each  subset.  Kruskal-Wallis  test  was  used  to 
compare CD45 transcript amount among TZL, cells CD5-positive sorted from reactive 
lymph nodes and CD45-positive high grade T-cell  lymphomas. A  Mann-Whitney test 
was used to compare CD45 transcript amount between TZL samples with<  95% and 
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>95% neoplastic cells. The Kruskal-Wallis test was also performed to compare CD45 
DNA load among TZL, reactive lymph nodes and cells CD45-negative and CD5-positive 
sorted from TZL.
A non-parametric Spearman correlation analysis was used to determine the potential 
relationship between CD45 transcript amount and percentage of neoplastic cells in the 
TZL samples. 
Results
Fine needle aspirates from an enlarged lymph node were obtained from 57 dogs and 
included in the study. Diagnoses were as follow: 40 (70.2%) TZLs, 7 (12.3%) high-grade 
T-cell  lymphomas  and  10  (17.5%)  hyperplastic  lymphadenopathy.  Normal  and 
neoplastic cells were obtained with cell sorting from 3 non-neoplastic lymph nodes and 
3  TZLs,  respectively.  In  addition,  paraffin  embedded  lymph  nodes  from  2  cases 
diagnosed as reactive hyperplasia, 2 as Peripheral T-cell lymphomas (PTCL) and 2 as 
TZL were available for immunohistochemical analysis.
According to FC analysis, the percentage of CD45-negative neoplastic cells in the TZLs  
was 80.54 ± 14.9% (median 82.6%; min-max 30.77 -98.04%). The composition of the 
residual CD45-positive population was heterogeneous. One sample had a predominant 
(94.5%) population of granulocytes and the lymphoid population was composed of T-
cytotoxic (4.8%),  T-helper (1.4%) and B-cells (0.34%):  this sample was highly hemo-
contaminated  at  cytological  examination.  For  the  remaining  samples,  the  residual 
CD45-positive  population  was  composed  of  lymphoid  cells  alone,  with  a  mean 
percentage  of  36.57  ±  17.31%  (median  33.22%;  min-max  1.40–67.41%)  of  B-cells, 
34.72 ± 19.45% (median 33.63%; min-max 1.89–92.09%) of T-helper cells, and 18.75 ± 
14.64% (median 12.91%; min-max 0.72–60.15%) of T-cytotoxic cells. As expected, the 
CD45-negative and CD5-positive cells were not detected either in the reactive lymph 
nodes or in the high-grade T-cell lymphomas.
Immunohistochemical  results  showed  a  diffuse  CD45  membranous  expression  in 
PTCLs.  In  the  reactive  lymph  nodes,  CD45  positive  cells  were  located  both  in  the 
paracortex and in the germinal
centres; cells in the marginal and mantle zones were also CD45 positive, even with a  
lower intensity (Fig. 13). TZLs were diffusely negative (Fig. 14). 
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Data concerning CD45 transcript amount were obtained from 41 cases, including 31 
(75.6%) TZLs, 7 (17.1%) high grade T-cell lymphomas, and 3 (7.3%) sorted normal T 
cells. The mean neoplastic cells percentage in TZLs undergoing transcript analysis was 
80.23 ± 15.61% (median 82.6%; min max 30.77–98.04%); in particular, 26 (83.9%) cases 
had <95% neoplastic cells, whereas the remaining 5 (16.1%) cases had >95% neoplastic 
cells. Results of transcript analysis are shown in Fig. 15.  
Figure 13: representative image of CD45 protein positive staining. A and B: Peripheral T-cell Lymphoma. 
C: reactive lymphoid hyperplasia. T-lymphocytes within the paracortex and B-lymphocytes in the follicles  
show a diffuse 
CD45immunolabelling.
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BA
Fig.ure 14: representative image of CD45 protein staining in a T-zone lymphoma. Neoplasticlymphocytes 
are negative to CD45 immunolabelling.
A significant  difference  in  the  CD45  transcript  amount  was  detected  among  TZLs, 
normal  T  cells  and  high  grade  T-cell  lymphomas  (p  <  0.001).  mRNA  levels  were 
significantly lower in TZLs than in normal T cells and high grade T-cell lymphomas (p < 
0.001), respectively. No significant difference was found between normal T cells and 
high grade T-cell lymphomas (P = 0.138).
When  exploring  the  correlation  between  the  amount  of  CD45  transcript  and  the 
percentage of the neoplastic cells in TZL, a significant inverse correlation was detected 
between  CD45  mRNA  data  and  the  percentage  of  neoplastic  cells  (p  =0.010).  In 
addition, the amount of CD45 transcript was higher in the 26 TZL samples with < 95% 
neoplastic cells (mean = 0.37 ± 0.29) than in the 5 TZL samples with > 95% neoplastic 
cells (mean = 0.23 ± 0.16), although the difference was not statistically significant.
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Data concerning CD45 DNA load were obtained for 33 samples, including 24 (72.7%) 
TZLs,  3  (9.1%)  CD45-negative  cells  and CD5-  positive  cells  sorted  from TZLs  and 6 
(18.2%) non-neoplastic  lymph  nodes.  The mean neoplastic  cells  percentage in  TZLs 
undergoing DNA analysis was 81.95 ± 9.88% (median 83.26%; min-max 30.77–96.5%). 
Amplicon DNA sequencing confirmed (99–100%) the specificity of the amplification for 
both CD45 targets.
Results  are  shown  in  Fig.  15.  The  differences  among  subsets  were  not  significant 
irrespective of the reference gene considered (p =0.165 for CGI-119 and p = 0.895 for 
GAPDH).
Figure 15. CD45 transcript and DNA amount in canine T-zone lymphomas and in controls.Panel A: CD45 
transcript amount in canine T-zone lymphomas, sorted CD5-positive cells from reactive lymph nodes and 
high-grade T-cell lymphomas; CGI-119 was used as a housekeeping gene; CD45 transcript amount was 
significantly lower in T-zone
lymphomas than in the other two groups, respectively (p < 0.001). Panel B: CD45 DNA load in canine T-
zone lymphomas, sorted neoplastic cells from T-zone lymphomas and reactive lymph nodes; CGI-119 
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was used as a reference gene; no significant difference in CD45 DNA load was found among groups. 
Panel C: CD45 DNA load in canine T-zone lymphomas, sorted neoplastic cells from T-zone lymphomas 
and reactive lymph nodes; GAPDH was used as a reference gene; no significant difference in CD45 DNA 
load was found among groups.
Discussion
Until now, only few studies have described the clinical presentation of dogs with TZL. 
In agreement with previous data, adult dogs are usually affected, and there seems to 
be no sex predilection (Flood-Knapik et al., 2013; Seelig et al., 2014). 
In previous reports, Golden retrievers were the dominant breed, suggesting a possible 
genetic risk factor (Seelig et al., 2014).  Interestingly, no Golden retrievers were present 
in our case series, possibly being attributable to a different genetic  background among 
countries or, less likely, to a  lower prevalence of this breed in Italy. Further studies 
should be performed to highlight possible similarities and differences in the genetics 
within the Golden retriever population but in a recent study that we conducted with 
the European Canine Lymphoma network emerged (Comazzi et al., submitted) that no 
breed prevalence for TZL were found in European Golden retriever population.
Although staging was not undertaken in every dog, the majority of dogs in the present 
case series had an advanced clinical stage at presentation, in agreement with a previous 
study (Aresu et al., 2013). Despite this and in contrast to high grade T-cell lymphomas, 
prognosis was not inexorably poor, thereby questioning the utility of the WHO system 
to stage indolent lymphomas. It is possible that other variables may show a more useful 
prognostic significance for this lymphoma subtype.
When available, PB and BM were always infiltrated. Neoplastic cell percentages were 
mostly higher in PB samples compared with BM samples. This may be because of an 
overspill phenomenon, when nodal neoplastic cells are likely released into the blood 
circulation, rather than to BM invasion and homing.
A role might be played by the lack of CD45, since the inhibition of this phosphatase  
impaired motility and homing of both normal and leukemic humans cells in a recent  
study (Shivtiel et al., 2011). The small degree of BM infiltration might also explain the 
low prevalence of peripheral cytopenias reported in the present study and in the study 
by Seelig et al. (2014).
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The median survival in this study is comparable with those already reported in the 
literature (Seelig et al., 2014; Ponce et al., 2004) 
Interestingly, three dogs died within a short period from the diagnosis. Two of them 
showed clinical symptoms at diagnosis,  whereas substage was not reported for the 
third case. Substage b is a well-known negative prognostic factor in canine high grade 
lymphomas.  The  same  prognostic  significance  may  be  held  true  in  indolent 
lymphomas, thereby explaining the short survival of these dogs. 
About 10% of the cases included here developed a second malignancy. This event has 
already been reported in dogs (Marconato et al., 2011)  and people (Xu et al., 2013; 
Tajika et al., 2014) with lymphoma.
The causes underlying the development of second malignancies are still unclear, but 
treatment, above all alkylating agents, has been associated with subsequent malignant 
neoplasms in human medicine (Daniels et al., 2013; Ahmadzadeh et al., 2014; LeMieux 
et  al.,  2015).  Two  of  three  dogs  developing  second  malignancy  in  this  study  had 
received alkylating chemotherapy.
Another  possible  explanation  for  second  malignancy  development  is  a  genetic 
predisposition  to  cancer.  Indeed,  neoplastic  transformation  is  based  on  genetic 
abnormalities  of  many  different  genes  (oncogenes,  tumour-suppressor  genes  and 
stability genes), which can occur in the germ line, resulting in hereditary predisposition 
to  different  types  of  cancer  or  in  somatic  cells,  resulting  in  sporadic  tumours 
(Vogelstein et al., 2004).
The major limits of the first phase of the study are inherent to its retrospective nature.  
Indeed, for almost half of the included population, clinical data were missing because 
not reported or retrieved by the referring veterinarians. Also, staging workup varied 
among veterinarians, possibly leading to under-staging of cases. Finally, we were not 
able to perform survival analysis because of the huge variety of treatment regimens 
adopted. Unfortunately, treatment in dogs with lymphoma are not standardized yet 
and also the choice whether to treat or not is left to referring vets.
Interestingly, all the studies assessing the expression of CD45 protein in TZL by FC use  
the  same  antibody  clone  (YKIX716.13),  although  conjugated  with  different 
fluorochromes  (Martini  et  al.,  2013;  Seelig  et  al.,  2014).  In  the  present  study,  we 
analysed two cases of TZL via immunohistochemistry using a different antibody clone 
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and results confirmed FC analysis. Both techniques and clones could not detect CD45 
protein, thus confirming the lack of CD45 protein expression in canine TZL. 
Although we can not completely exclude partial modification of the protein during FC 
and IHC processing,  these preliminary results supported the hypothesis of a complete 
loss of CD45 in TZLs.
To investigate this scenario, we inquired whether CD45 transcript was also reduced in 
canine TZL and consequently if CD45 gene was still represented in the genome of the 
neoplastic  cells.  To answer this hypothesis,  we designed two quantitative real-time 
PCR  experiments  in  order  to  investigate  the  transcript  amount  and  DNA  load, 
respectively. In the study setting, a major limiting factor was related to the selection of  
control lymphocytes for both transcript and DNA analyses. Indeed, CD45 is differently 
expressed in the various canine leukocyte subclasses, also depending on the activation 
status (Goto-Koshino et al., 2014), and CD45 transcript amount may vary accordingly. 
In particular, CD45 is expressed at lower levels in B-cells than in T-cells (Comazzi et al., 
2006):  thus,  inclusion of B-cells  in the control  group for  transcript amount analysis 
would  have  affected  results  concealing  possible  differences  between  TZLs  and 
controls. Respect to this, we  selected as control high grade T-cell lymphomas and a 
pure T-cell population obtained by cell sorting from non-neoplastic lymph nodes.
Based  on  our  results,  CD45  transcript  amount  resulted  significantly  lower  in  TZLs  
compared to  high-grade  T-cell  lymphomas and normal  T-cells.  Albeit  a  small  CD45 
transcript amount was detected in TZLs, this might be associated to the contamination 
of  relevant  residual  normal  lymphocytes  in  the  samples  obtained.  This  was  well  
demonstrated when comparing the CD45 gene expression to the number of neoplastic 
cells in these tumors. The lowest CD45 transcript amounts were associated to TZLs 
with  the  highest  percentage  of  neoplastic  cells  and  consequently  the  lowest 
percentage of residual lymphocytes. Taken together, these results suggest that CD45 
transcript is virtually absent in TZL neoplastic cells.
For DNA load analysis, high grade T-cell lymphomas were excluded as controls due to  
the possible presence of genetic abnormalities that occur in cancer cells, leading to 
unpredictable  biases.  In  contrast,  the  selection  of  non-neoplastic  lymph  nodes  as 
controls, potentially should not interfere with this result, as variations in genes copy 
number are not expected in reactive lymph nodes, at least in the CD45 gene. However,  
67
the in silico identification of the reference gene for DNA load analysis was complicated 
by two biological variables. First, copy number variations may eventually occur at gene 
level  biasing the results  and second,  no relevant  data  are  published about  genetic 
modifications of canine TZL. Thus, primers for two different genes were designed for 
our analysis and results showed a similar load in TZLs and controls, irrespective of the 
reference gene used, demonstrating that CD45 gene is not deleted in canine TZL.
Primers design was also challenging, as different isoforms of CD45 exist obtained by 
alternative RNA splicing (Dupéré-Minier et al.,  2010) and the gene comprises many 
introns (www.ensembl.org). Furthermore, we designed primers that were adapted to 
amplify  a  transcript  fragment  common to  all  CD45  isoforms,  and  a  gene  segment 
specifically  encoding  for  the  transcript  fragment  was  amplified.  By  doing  this,  we 
reached a double goal: first, we included all CD45 isoforms in our analysis; second, we 
described the different fate of a single sequence at two different levels (transcript and 
DNA).  Many  different  mechanisms  may  cause  CD45  gene  transcription  switch  off,  
including genetic, epigenetic, and genomic abnormalities.
Still, gross chromosome or gene deletions are unlikely. Indeed, we were able to detect 
the presence of CD45 gene in TZL cells. In addition, Seelig et al. (2014) reported that 
there is no evident loss of the telomeric end of chromosome 7, where CD45 is located,  
although no scientific data are described in their publication. All other mechanisms are 
still possible and should be evaluated via further studies.
Different studies in human medicine investigated the importance of CD45 in normal T- 
and B-cells, highlighting its role in cell maturation, signal transduction and apoptosis 
mediator (Pingel and Thomas, 1989; Kishihara et al., 1993; Byth et al., 1996; Lesage et  
al.,  1997;  Fortin  et  al.,  2002;  Pang  et  al.,  2009).  Its  involvement  in  neoplastic 
transformation  may  be  suspected,  but  this  has  never  been  demonstrated. 
Interestingly, different oncogenes are located near CD45 gene in canine chromosome 
7,  including  ABL2,  AKT3,  YES1  and  some  members  of  the  Ras  family 
(www.ensembl.org).  These  oncogenes  may  play  a  role  in  cancer  development  in 
human leukemias  and lymphomas (Mao et al.,  2003; Huang et al.,  2010; Kim et al., 
2015;  Roberts  and Mullighan,  2015).  Perturbation of  methylation  on the promoter 
regions  of  these  genes  or  genomic  abnormalities  on  a  large  segment  of  canine 
chromosome  7  may  cause  impaired  transcription  of  any  of  these  oncogenes 
68
participating to the tumorigenesis. Thus, it cannot be excluded that the absence of 
CD45 protein is only a phenotypic epiphenomenon, with minimal involvement in the 
tumor biology. 
Further studies are needed, assessing possible alterations in oncogenes activation. The 
whole CD45 gene sequencing would probably solve the limitations of the second phase 
of  the  study,  where  only  a  fragment  of  CD45  gene  specifically  encoding  for  the 
transcript fragment selected was amplified. Thus, mutations, short deletions or base 
pair variations may occur upstream of the amplified fragment, remaining unnoticed to 
our analysis, but still preventing gene transcription.
In conclusion, the first phase of the present study reports the clinical presentation and 
the outcome of a series of dogs diagnosed with CD45- negative small clear cell/TZL.  
The majority of  dogs had stage V disease, were not symptomatic (substage a)  and 
peripheral  cytopenias  were  uncommon.  The  reported  predisposition  of  Golden 
retrievers to develop TZL was not confirmed by our results. 
Canine TZL is known to bear a good prognosis with long survival times, even if a subset 
of dogs in our study died within few weeks. Further prospective studies on larger case 
series, with standardized staging workup and treatment regimens, and longer follow-
up times are needed to confirm our results.
The second phase confirms the lack of CD45 protein in canine TZL, irrespective of the 
different techniques and antibody clones used. Based on our results, this phenotypic 
aberrancy is likely due to the absence of gene transcription, as CD45 DNA was present, 
whereas CD45 transcript was virtually absent in the neoplastic cells.
The results of the present study were preliminary presented in poster form at the 14-
ICML  (Martini V, Cozzi M, Aricò A, Poggi A, Riondato F, Marconato L, Aresu L, Comazzi 
S. EVALUATION OF CD45 PROTEIN EXPRESSION AND TRANSCRIPT  IN CANINE SMALL 
CLEAR CELL / T-ZONE LYMPHOMA) and then published on two separate papers on peer 
review international journals (“V. Martini, L. Marconato, A. Poggi, F. Riondato, L. Aresu, 
M. Cozzi and S. Comazzi.  CANINE SMALL CLEAR CELL/T-ZONE LYMPHOMA:  CLINICAL 
PRESENTATION AND OUTCOME IN A RETROSPECTIVE CASE SERIES.  Vet Comp Oncol. 
2016 Aug;14 Suppl 1:117-26”. “V. Martini, M. Cozzi, A. Aricò, G. Dalla Rovere, A. Poggi, 
F.  Albonico,  M.  Mortarino,  E.  Ciusani,  L.  Aresu,  S.  Comazzi.  LOSS  OF  CD45  CELL 
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SURFACE EXPRESSION IN CANINE T-ZONE LYMPHOMA RESULTS FROM REDUCED GENE 
EXPRESSION. Vet Immunol Immunopathol. 2017 May;187:14-19”.)
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3.3 CANINE NODAL MARGINAL ZONE LYMPHOMA: INSIGHT INTO THE 
BIOLOGICAL BEHAVIOUR
Background
In  human  and  veterinary  medicine,  the  Marginal  Zone  Lymphoma  (MZL)  group  is 
divided  into  3  subtypes  according  to  the  World  Health  Organization  (WHO) 
classification (Swerdlow et al., 2016): Mucosal Associated Lymphoid Tissue Lymphoma 
(MALT), splenic Marginal Zone Lymphoma (sMZL) and nodal Marginal Zone Lymphoma 
(nMZL). These 3 entities are described as separate diseases in terms of biology, clinical  
presentation and behaviour. The major diagnostic criterion is the site of presentation 
(Ferreri and Zucca, 2007). MALT is relatively common, encompassing 5% to 8% of all 
NHLs and it most frequently involves the gastrointestinal tract (66% of all MALT cases),  
occurring
in  patients  with  a  history  of  autoimmune  disorders  and  chronic  inflammation 
(Olszewski and Castillo, 2013; Zucca and Bertoni, 2016). SMZL and nMZL are quite rare, 
each comprising less than 1% of NHL. sMZL is a symptomatic disease which at onset 
usually involves spleen, bone marrow (BM) and peripheral blood (PB).  Many patients 
with  nMZL  show regional  (head  and  neck)  lymphadenopathy,  but  more  than  70% 
present  with  stage  III/IV  disease  (according  to  the  Ann  Arbor  staging  scheme) 
(Angelopoulou et al., 2014; Tadmor and Polliack, 2017). The prognosis is reported to 
be less favourable for nMZL than for MALT and sMZL (Nathwani et al., 1999). 
The same classification is adopted for the dog; MALT lymphoma has not been well 
described in canine patients. It is rare, and predominantly involves the respiratory and 
intestinal  tracts,  but  other  locations  have  been occasionally  reported,  such  as  the 
salivary  gland  and  eyelid  (Valli  2007;  Hong  et  al.,  2011).  Canine  sMZL  has  been 
described in terms of presentation and outcome. Unlike human sMZL, the majority of 
canine  sMZL  represents  an  incidental  finding  during  physical  examination  and 
abdominal ultrasound. Canine sMZL has an indolent clinical course and splenectomy, 
with or without systemic chemotherapy, is usually curative  (Stefanello et al.,  2011; 
O'Brien et al., 2013; Van Stee et al., 2015).
Canine nMZL is  generally classified as  an indolent lymphoma,  having a low mitotic 
index and a slow clinical progression (Valli  2007). However, in spite of the putative 
indolent nature, some dogs with nMZL may experience an aggressive disease course 
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(Valli  et  al.,  2006;  Flood-Knapik  et  al.,  2012;  Valli  et  al.,  2013;  Aresu  et  al.,  2015; 
Marconato et al., 2015). Specific studies focused on clinical presentation and behaviour 
of canine nMZL are lacking. The aim of this study is to describe the clinico-pathological  
features and outcome in a cohort of dogs with histologically confirmed  MZL with a 
primary nodal presentation, thus better characterize this tumour as a single disease 
entity. 
Material and Methods
Inclusion criteria
Medical records of dogs with lymphoma referred to the Centro Oncologico Veterinario 
between  2012  and  2016  were  retrospectively  reviewed  for  cases  with  a 
histopathological diagnosis of nMZL (Valli et al., 1981; Valli et al., 2011) To be eligible  
for enrolment, dogs were required to undergo a complete staging work-up, including 
complete blood count (CBC),  serum biochemistry (including Lactate Dehydrogenase-
LDH-activity  and  Ionized  Calcium  concentration),  cytology  and  flow  cytometric 
immunophenotyping on a lymph node (LN) aspirate, thoracic radiographs, abdominal 
ultrasound, fine-needle aspiration of liver and spleen regardless of their sonographic 
appearance, and PB and BM infiltration degree assessed by flow cytometry (FC). The 
abovementioned work-up is standard of  care in the Centro Oncologico Veterinario. 
Previous lymphoma-directed therapy (including steroids) was an exclusion criteria.
Flow cytometry
FC was performed on fresh samples of LN aspirates as described before (first study of 
the thesis). PB and BM involvement were defined as the presence of cells of B-lineage 
(CD21+) of medium to large size. Although specific cut-off values for defining tumour 
infiltration in PB and BM have not been defined for canine MZL, these were set at 
0.56% for PB and 2.45% for BM, respectively, out of the total CD45+ cells. These values 
were derived from a recent study on the analytical and diagnostic performances of FC 
to  detect  PB  and  BM neoplastic  infiltration  of  large B-cell  lymphoma cells  in  dogs 
(Riondato et al., 2016). Cytological smears of LN, PB and BM aspirates were evaluated 
in parallel with FC in order to confirm cell morphology, evaluate mitotic figures and 
detect neoplastic infiltration (Comazzi and Gelain, 2011).
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Immunohistochemistry
A  peripheral  enlarged  LN  was  surgically  removed,  formalin  fixed  and  paraffin 
embedded,  stained  with  haematoxylin  and  eosin,  and  examined  by  a  veterinary 
pathologist. For immunohistochemistry, antibodies against CD3 (clone F7.2.38; Dako, 
Atlanta, Georgia, USA), CD5 (clone CD5/54/F6; Dako), CD79a (clone HM57; Dako) and 
CD20 (clone RB-9013-P,  Thermo Fisher Scientific)  were used on paraffin-embedded 
sections. The diagnosis of nMZL was confirmed according to the WHO classification 
(Valli et al., 2011).
Treatment and outcome
Dogs were treated with a 20-week combination induction chemotherapy, consisting of 
L -Asparaginase (week 1), vincristine (weeks 2, 3, 4, 13), cyclophosphamide (weeks 2, 
13), doxorubicin (week 7, 16), lomustine (weeks 10, 19) and prednisone (weeks 1-20),  
as previously described (Marconato et al., 2015). Dogs whose owners wished to pursue 
immunotherapy, also received an intradermal injection of 0.5 mL autologous vaccine 
on weeks 4, 5, 6, 7, 12, 16, 20 and 24. The vaccines consisted of tumour-derived heat  
shock  protein-peptide  complex  coupled  with  hydroxyapatite  ceramic  powder 
(Marconato et al., 2014; Marconato et al., 2015). Response to treatment was classified 
as complete remission (CR), partial remission (PR), stable disease (SD), or progressive 
disease (PD) (Vail et al., 2010). Response was evaluated at each therapeutic session 
and was required to last for at least 28 days.
Statistical analysis
Time  to  progression  (TTP)  was  calculated  as  the  interval  between  initiation  of 
treatment and PD or relapse, whereas lymphoma-specific survival (LSS) was measured 
as the interval between initiation of treatment and lymphoma-related death. Dogs lost 
to follow-up or dead for lymphoma-unrelated causes before PD, as well as those still in 
CR at the end of the study, were censored for TTP analysis. Dogs alive at the end of the  
study, lost to follow-up or dead due to causes other than lymphoma were censored for 
LSS analysis. Response rate (RR) was defined as the sum of all dogs achieving CR and 
PR.  Survival  was  analysed  according  to  the  method  of  Kaplan-Meier.  Differences 
between survival curves were evaluated with the log-rank test. Multivariate analyses 
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were performed using a Cox stepwise proportional hazard model to identify variables 
that  might  be  of  independent  significance  influencing  TTP  and  LSS.  Variables 
considered were breed (mixed or pure),  sex, age (cut-off arbitrarily set at 7 years), 
weight (cut-off arbitrarily set at 10 kg), packed cell volume (PCV) (normal, decreased, 
increased),  platelet  count  (normal,  decreased,  increased),  serum  lactate 
dehydrogenase (LDH) activity (normal, decreased, increased),  serum ionized calcium 
concentration (normal, decreased, increased), substage (a or b), spleen involvement 
(yes or no), PB infiltration (yes or no), total lymphocyte count in peripheral blood (as a 
continuous variable), BM infiltration (yes or no), and extranodal site involvement (yes 
or no). Binomial logistic regression was performed to investigate the independence of 
LDH activity and response to treatment with respect to the abovementioned variables. 
Statistical analysis was performed via SPSS v20.0 for Windows (IBM, New York, USA).  
Significance was set at P ≤ .05 for all tests.
Results
Thirty-five dogs met the inclusion criteria. Among them, 29 have been included in a 
previous paper (Marconato et al., 2015). Nine dogs (25.9%) were mixed breeds, while 
26 (74.3%) were pure breeds (Table 3).
The  median  age  was  7.0  years  (mean:  7.6  ±  3.1  years,  range:  3.0-15.0  years).  In 
particular, 15 dogs (42.9%) were younger than 7 years, while 20 dogs (57.1%) were 7 
or more years. Median weight
was 24.6 kg (mean: 23.0 ± 12.5 kg, range 3.0-44.4 kg), with 7 dogs (20%) less than 10  
kg and 28 (80%) 10 kg or more. There were 21 (60%) males (3 neutered) and 14 (40%) 
females (5 spayed).
All dogs were presented with generalized lymphadenopathy and this was the reason 
for initial presentation. Lymphadenopathy had been present for a median of 20 days 
(range: 2-120 days). At the time of diagnosis, 23 (65.7%) cases were asymptomatic,  
while 12 (34.3%) showed non-specific clinical symptoms. All dogs had stage V disease. 
Splenomegaly was detected during physical examination in 20 (57.1%) dogs. However, 
the percentage of cases with splenic involvement rose up to 97.1% (34 dogs) based on 
abdominal ultrasound and cytological evaluation. In these dogs, abdominal ultrasound 
revealed splenomegaly; the spleen showed abnormal echogenicity and echo-structure, 
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with  a  diffusely  heterogeneous  parenchyma.  Splenomegaly  was  considered  as 
moderate in 30% and severe in 70% of the cases. Focal lesions were often observed 
(70% of the  dogs),  represented by 1 to 2 cm large hypoechoic nodules or multiple 
small hypoechoic nodules, with a consequent spotted appearance of the parenchyma 
(“honey-comb  appearance”).  The  sonographic  findings  suggested  parenchymal 
infiltration,  confirmed  by  cytological  evaluation  showing  a  homogeneous  or  highly 
prevalent population of medium sized blast cells, often with macronucleoli.
The liver was infiltrated in 27 (77.1%) dogs, as documented by sonographic changes 
and confirmative cytology. In addition, 10 (28.6%) dogs had extranodal involvement, 
with the lung present (9 cases),  while only 1 dog had more than 1 extranodal  site 
documented  (eye  and  bladder).  Lymphoma  at  extranodal  sites  was  diagnosed  by 
imaging  and  confirmative  cytology  in  all  but  one  cases;  the  dog  with  ocular 
involvement  had  a  resolution  of  bilateral  uveitis  after  the  first  chemotherapy 
administration, consistent with a presumptive neoplastic nature of the lesion.
Cytologically, the neoplastic cells were medium sized and characterized by nuclei of 
intermediate  size  (1.5-2  times  the  size  of  a  red  blood  cell)  with  fine  chromatin,  
prominent  single  central  nucleoli  and  a  moderate  amount  of  weakly  basophilic 
cytoplasm. Few residual mature lymphoid cells were also present. Sometimes a scant 
population  of  larger  lymphoid  cells,  defined  as  centroblasts  with  anisocytosis  and 
anisokaryosis, was observed. Mitotic index was low with less than 1 mitotic figure/5 
high power field (HPF) (×40) (Fig. 16). 
FC  confirmed  the  B-cell  lineage  of  the  neoplastic  cells.  CD21  and/or  CD79a+  cells  
represented the predominant cells in LN samples (median: 82.7%, range: 42.0-95.7, 
mean: 78.1 ± 15.6) (Wilkerson et al., 2005). They showed median forward scatter (FSC)  
of 432.8 (mean: 440.5 ± 46.2, range: 357.1-521.6) (Fig.17). An admixed population of  
small residual lymphocytes was also present, yet scarce in percentage (median: 6.4%, 
mean 12.4 ± 18.2%, range: 3.0%-22.8%). Regarding PB and BM infiltration, 34 (97.1%) 
dogs had PB involvement, with a median percentage of neoplastic cells of 6.4% (mean: 
12.4 ± 18.2%, range: 0.7%-53.5%), while BM was infiltrated in 20 (57.1%) cases, with a 
median  percentage  of  neoplastic  cells  of  8.1%  (mean:  12.5  ±11.4%,  range:  3.0%-
51.6%). 
Histology and immunohistochemistry were performed in all cases. 
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Table 3: Clinical presentation and outcome of 35 dogs with nodal marginal zone lymphoma
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Figure 16:  cytological smear of a nMZL,  characterized by nuclei of  intermediate size with prominent 
single  central  nucleoli  and  abundant  lightly  stained  cytoplasm  and  with  mitoses  absent  except  in 
advanced cases. A mixture of some immunoblasts and centroblasts sometimes is present.
Histological grade was available for 31 cases; among them, 30 were at a late stage of 
development,  characterized by a  diffuse  growth pattern and loss  of  follicle-related 
architecture.  The  capsule  was  documented  to  be  thinned  and  taut.  The  greatest 
proportion (80%-90%) of cells was medium sized (1.5-2 times the red blood cell), with 
scant eosinophilic cytoplasm, round nucleus and single prominent central nucleolus. 
The remaining 10% to 20% of the LN population was represented by small  mature 
lymphocytes. Sometimes, large cells defined as centroblasts and immunoblasts were 
observed; mitotic activity of these cells was variably, low to moderate and the mean 
mitotic index ranged from 0 to 5 in 10 HPF (×40) (Aresu et al., 2015). Tingible body 
macrophages  were  present.  CD79a  and  CD20  immunohistochemical  positivity 
confirmed B-cell origin (Valli 2007; Valli et al., 2011).
Regarding CBC at diagnosis, 3 (8.6%) dogs were anaemic (PCV < 37%), 31 (88.5%) had a 
PCV within the reference interval,  and 1 (2.9%) dog had an increased PCV (57%);  4 
(11.4%) dogs had thrombocytopaenia (platelet count <200×103/μL confirmed by smear 
evaluation),  while  31  (88.5%)  had  a  normal  platelet  count.  Thirty-four  dogs  were 
normocalcemic, while 1 dog had a decreased
ionized calcium concentration. LDH activity (< or ≥300 IU/L) was increased in 14 (40%) 
cases, while it was normal in the remaining 21 (60%) dogs.
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Binomial logistic regression revealed no significant correlation between LDH activity 
and all abovementioned variables. No correlation was found between PB lymphocyte 
count and TTP or LSS.
Figure  17:  flow cytometric  scattergrams representing lymph node aspirate of  a  nMZL.  Events  were 
displayed at first
based on morphological properties (lA) and a gate (R1) was set to exclude platelets and debris. R1 cells 
were then displayed based on CD21-alexa 647 fluorescence and FSC . Neoplastic cells were medium to 
large-sized positive for CD21 antibody (B, up and right quadrant). Small lymphocytes reffered to residual 
normal population were present (B, low and left quadrant.
Treatment and outcome
Thirty-four dogs were treated with chemotherapy, and 18 (52.9%) received concurrent 
immunotherapy.  One dog received no treatment at  all  and was excluded from the 
survival analysis. TTP and LSS for this dog were 49 and 340 days, respectively. Of the 34 
dogs that were treated, 25 completed the planned  treatment schedule and 9 died 
during treatment due to PD. Among all  others, 20 (80%) achieved CR (of those, 13 
received concurrent immunotherapy) and 5 (20%) achieved PR (of those, 3 received 
concurrent immunotherapy).
Sixteen dogs having completed the planned protocol received rescue chemotherapy 
after  documentation  of  PD:  12  received  a  CHOP  (cyclophosphamide,  doxorubicin, 
vincristine,  prednisone)-based  protocol,  whereas  3  were  treated  with  DMAC 
(dexamethasone, D-actinomycin, melphalan, cytosine arabinoside). A second CR was 
obtained in 14 of them.
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Binomial  logistic regression revealed that platelet count was significantly associated 
with treatment response (P = 0.033). Thrombocytopenic dogs had a lower probability 
of responding to treatment (odds ratio: 0.071; 95% confidence interval: 0.006-0.810). 
RR was 50% for dogs with thrombocytopaenia and 80% for dogs with a normal platelet 
count. Overall median TTP was 149 days (range: 1-994 days). None of the investigated 
variables significantly influenced TTP. Overall, median LSS was 259 days (range: 5-1605 
days).  Four dogs were alive at data analysis closure after 601, 613, 1016 and 1605 
days. Three dogs died of tumour-unrelated causes after 93, 181 and 238 days. Cause of 
death was due to lymphoma in the remaining 28 dogs. LDH activity (P = 0.025) and 
substage (P = 0.008) significantly influenced  LSS. In particular, median LSS was 385 
days (range: 111-1605 days, n = 20) for dogs with a normal LDH serum level, and 211 
days  (range:  5-601 days,  n  = 14)  for  dogs  with increased LDH; asymptomatic  dogs 
(substage a) had a median LSS of 399 days (range: 93-1605, n = 22), compared with 
125 days (range: 5-613, n = 12) for symptomatic dogs (substage b). Multivariate Cox’s  
proportional  hazard regression analysis showed the influence of platelet count (P = 
0.01) on LSS.
Discussion
This  study  describes  the  clinical  presentation  and  outcome  of  35  dogs  with 
histologically confirmed nMZL. Despite the retrospective nature of the design, data 
concerning initial staging, treatment and follow-up were available for all dogs, thereby 
providing robust information. Canine nMZL is considered an indolent disease (Valli et 
al., 2011; Aresu et al., 2015), however the published studies describing the clinical and 
morphological features of indolent lymphomas  suggest that a subset of nMZL cases 
may display a more aggressive clinical course (Valli et al.,  2006; Flood-Knapik et al., 
2012; Valli et al., 2013; Aresu et al., 2015; Marconato et al., 2015).
Indeed, based on our results, the indolent designation may not always be appropriate, 
as  all  dogs  had  generalized  lymphadenopathy  and  one  third  of  them  were 
symptomatic at initial presentation. In contrast with previous reports, suggesting that 
nMZL typically does not cause any  systemic involvement (Valli 2007), all dogs in the 
present cohort but one had PB involvement and 57.1% had BM involvement, while 
one-third of them had extranodal involvement. The cause for the discrepancy between 
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PB and BM infiltration is  unclear,  but an overspill  of  neoplastic  cells  from affected 
nodes in the absence of true BM invasion could be a possible explanation, similar to 
what  has  been  described  for  T-zone  lymphoma  (second  study  of  the  thesis). 
Alternatively, it may be due to the different cut-offs used to define positive PB and BM 
samples and to the use of FC for staging, which is a very sensitive tool to detect BM 
and  PB infiltration  compared with  standard  light  microscopy  (Comazzi  and  Gelain, 
2011). Although splenic involvement was detected in 97% of cases, a primary splenic 
MZL was  considered unlikely,  based on  the integration  of  clinical  and  pathological 
data. Indeed, in canine primary sMZL, the spleen is usually the only site involved, and 
the diagnosis is frequently incidental (Stefanello et al., 2011; O'Brien et al., 2013; Valli 
et al.,  2006). In this study, ultrasonographic findings including splenomegaly, diffuse 
heterogeneity and hypoechoic nodular lesions suggested diffuse secondary infiltration 
of the parenchyma. Conversely, primary splenic MZL is characterized by a solitary focal 
hypoechoic  mass  without  any  changes  of  the surrounding  tissue (Stefanello  et  al., 
2011; O'Brien et al., 2013; Valli et al., 2011). 
In  humans,  nMZL  is  defined  by  the  WHO classification  as  “a  primary  nodal  B-cell 
neoplasm that morphologically resembles LNs involved by MZL of extranodal or splenic 
types, but without evidence of extranodal or splenic disease.” This implies that also in  
humans the diagnosis of nMZL is mainly based on the pattern of dissemination of the 
disease,  essentially  based  on  the  fact  that  sMZL  involves  the  spleen  without 
concomitant  peripheral  lymphadenopathy,  while  nMZL  does  not  have  a  clinical 
evidence of extranodal or splenic disease (Swerdlow et al., 2016; Van den Brand et al., 
2013). In spite of these considerations, we cannot definitely rule out a primary splenic 
origin of the tumour with a secondary late dissemination to peripheral nodes. 
For  the  cases  included  in  this  study,  we  were  able  to  evaluate  the  neoplastic 
population by means of 3 different techniques, namely cytology, histopathology and 
FC. The different techniques gave concordant and overlapping information: samples 
mainly  comprised  medium-sized  cells,  but  sometimes  were  accompanied  by  a 
population of centroblasts/immunoblasts and scant resident small lymphocytes.
These  features  also  correspond  to  those  previously  described  in  the  literature  for 
humans, where the presence of sheets of centroblasts appears to be related to disease 
progression  and  tumour  transformation  into  large  B-cell  lymphoma  (Kaur  2011). 
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Indeed, histology revealed that all cases but one were at a late stage of development,  
characterized by a diffuse growth pattern and loss of the follicle-related architecture. 
The only dog with the classical histologic marginal presentation and a slight PB and BM 
infiltration experienced long LSS (680 days). More cases are needed to define if the 
histological  architecture  pattern  may  be  independently  associated  with  a  differing 
clinical behavior. 
Based on the above, it may be hypothesized that late-stage nMZL behaves clinically 
like  high-grade  lymphomas,  with  a  tendency  to  spread  systemically.  Accordingly, 
Richards et al. (2013) found molecular similarities between nMZL and diffuse large B-
cell lymphoma (DLBCL), suggesting that these conditions might represent a continuous 
spectrum of the same disease. 
Approximately  one-third  of  dogs  died due to  lymphomas  within  6  months  despite 
treatment,  thereby  exhibiting  a  poor  outcome  that  contrasts  with  the  “indolent” 
tumour designation.  This  discrepancy is likely due to the different inclusion criteria 
among studies. Equally, the case selection of the current study might be biased as dogs 
with generalized lymphadenopathy are more likely to be referred to a referral centre 
and  undergo  a  full  staging  work-up.  Indeed,  this  is  the  first  case  series  focused 
exclusively on nMZL, with strict staging criteria. Most of the studies published in the 
veterinary literature include many different lymphoma subtypes or are limited to small  
case series with incomplete staging and follow-up data (Valli et al., 2006; Flood-Knapik 
et  al.,  2012;  Valli  et  al.,  2013).  Overall,  TTP  and  LSS  were  disappointingly  low, 
suggesting that the CHOP-based protocol used in the current series of dogs may not be 
the best option. 
Regarding prognostic factors, thrombocytopenic dogs had a significantly lower RR and 
shorter  LSS.  Thrombocytopenia  is  reported  in  10%-13%  of  cancer-bearing  dogs 
(Grindem et al., 1991; Botsch et  al., 2009), and is generally considered to be a poor 
prognostic factor (Valli 2007; Zemann et al., 1998; Moore et al., 2001). Substage b was 
an additional independent risk factor, in agreement with previous studies, showing a 
correlation with a poor outcome (Teske et al., 1994; Jagielski et al., 2002). Increased 
LDH serum level was also significantly associated with a shorter LSS. An increased LDH 
level at diagnosis has been associated with a shorter survival in people with indolent 
81
lymphoma (Bastion et al., 1991; Lopez et al., 1994). It may be possible that the same 
holds true in dogs.
Surprisingly, PB and BM involvement were not significantly associated with outcome. 
This is in contrast with what has been described for DLBCL (Marconato et al., 2013). 
The  cut-off  values  may  have  influenced  the  definition  of  stage.  It  must  be 
acknowledged that the cut-off values used in the current study and extrapolated from 
previously published data may be inappropriate for MZL, due to the smaller size of 
neoplastic  cells  that  impede  discrimination  between  neoplastic  and  reactive  B-
lymphocytes. A specific validation study is needed to define the correct FC approach 
for staging MZL (Riondato et al., 2016).
The main limitation of this study is the absence of cases with nodular presentation and 
earlier disease stages (I-IV).  This prevents extrapolation about the clinical  course of 
nMZL and the clinical significance of PB and BM involvement. As all dogs enrolled in 
the present  study  had generalized lymphadenopathy,  it  is  possible  that  dogs  were 
initially asymptomatic for a long time and during that time regional lymphadenopathy 
may have gone unnoticed.
In conclusion, dogs with nMZL may present at an advanced stage of disease, with an  
overall poor prognosis despite the indolent designation. Due to the significant clinical  
interest, the issue of dose intensity should be further explored in dogs with nMZL.
The results of the present study were preliminary presented as an oral presentation at  
the 18th
ESVCP, ESVONC  congress in Nantes (FRA) (Cozzi M, Marconato L, Martini V, Aresu L, 
Riondato  F,  Rossi  F,  Stefanello  D,  Comazzi  S. “CANINE  NODAL  MARGINAL  ZONE 
LYMPHOMA:  DESCRIPTIVE  INSIGHT  INTO  THE  BIOLOGICAL  BEHAVIOUR”)  and  then 
published on a paper on peer review international  journals  (Cozzi  M, Marconato L, 
Martini  V,  Aresu  L,  Riondato  F,  Rossi  F,  Stefanello  D,  Comazzi  S.  “CANINE  NODAL 
MARGINAL  ZONE  LYMPHOMA:  DESCRIPTIVE  INSIGHT  INTO  THE  BIOLOGICAL 
BEHAVIOUR”. Vet Comp Oncol. 2018 Jun;16(2):246-252)
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3.4 EVALUATION OF PUTATIVE PROGNOSTIC MARKERS IN CANINE B-CELL 
CHRONIC LEUKEMIA: A PRELIMINARY STUDY
Background
B cell  chronic  lymphocytic leukemia (B-CLL)  is  a common hematological  disorder in 
dogs, consisting in a clonal expansion of malignant mature B lymphocytes. Although B-
CLL is not the most diffuse subtype of chronic lymphocytic leukemia in dogs this entity  
show a particular comparative interest for the strong similarity from clinical, clinico-
pathological  and biological  behavior  and outcome with human chronic  lymphocytic 
leukemia (Comazzi  et al.,  2015; Rout et al.,  2018).  Up to 50% of affected dogs are 
asymptomatic  at  presentation  and  incidental  lymphocytosis  is  often  noted  during 
routine  blood  work  or  senior  health  profiling.  Similarly  to  humans,  B-CLL  affects 
patients  of  middle-elderly  age,  most  often  exhibiting  indolent  behavior,  but  some 
patients experience a more progressive form of the disease (Vail et al., 2001; Moore 
and Vernau, 2003; Comazzi et al., 2011; Workman HC and Vernau W., 2003; Williams 
et al., 2008; Comazzi  et al, 2015; Bromberek et al, 2016). 
A substantial heterogeneity exists in canine chronic lymphocytic leukemia with marked 
variation  in  classification  and  outcomes  within  and  among  subtypes.  Our  research 
group identified immunophenotype as a predictor of survival but the outcome, mainly 
of  B-CLL  remains  highly  variable  (Comazzi  et  al.,  2011)  and,  to  date,  no  specific 
prognostic markers have been identified. In human medicine, several  investigations 
have  made  to  identify  subgroups  of  B-CLL  patients  with  different  outcome  using 
various panels of surface and cytoplasmic markers, including lymphocyte antigens, cell-
adhesion molecules, integrins, or complement regulatory proteins (Huang et al., 2011). 
High  expressions  of  Zeta-associated  protein  70  (ZAP-70)  and  cyclic  ADP  ribose 
hydrolase (CD38) have been recognized as strong adverse risk factors in human's B-CLL 
(Moreno and Montserrat, 2008, Rossi et al 2010) being correlated with the mutational 
status of IgVH. Some studies have proven that these molecules are expressed also by 
canine cells, but the possible significance in canine B-CLL is still unknown (L.M. Smyth 
et al., 2006; Mortarino et al., 2009). 
Other flow cytometric markers also have been published for their prognostic potential 
in  human's  CLL.  Several  studies  have  investigated  the  prognostic  significance  of 
Interleukin-2 receptor alpha chain (CD25) expression, with contradictory results. Two 
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earlier reports (Hjalmar et al., 2002, Tefferi et al., 1997) showed that patients with CLL  
whose cells  expressed CD25 had a worse outcome than those with CD25-negative 
cells.  In  contrast,  other  studies  reported  the  opposite  situation,  suggesting  high 
expression of CD25 as linked to a good prognosis B-CLL ( Zucchetto et al., 2005; Capello 
et al., 2006;  Shvidel et al., 2012). 
The expression of CD25 has been investigated also in cells from canine lymphoma and 
leukemia patients  (Dickerson et  al.,  2002;  Mizutani  et  al.,  2016).  In  particular,  one 
recent publication showed that the progression-free survival was significantly shorter 
in CD25-high group than that in CD25-low group. The study was conducted on acute 
leukemias  and  several  lymphoma  subtypes,  but  the  clinical  significance  of  CD25-
positivity has not been explored in CLL (Mizutani et al., 2016).
The  nuclear  protein  Ki67  has  been  widely  used  to  assess  clinical  behavior  and 
determining the outcome in various human malignancies and in some solid tumors of 
the dog (Brown and Gatter, 2000; Sholzen and Gerdes, 2000; Endl and Gerdes, 2000; 
Broyde et al, 2009; Fonseca-Alves et al 2015; Fonseca-Alves et al 2017; Brunetti et al 
2017).  A recent study on canine lymphoma suggested the determination of ki67 by 
flow cytometry for the early detection of lymphomas transforming from low grade to 
high  grade  (Poggi  et  al.  2013),  while  other  studies  found Ki67  as  an  independent 
predictor for survival in treated high-grade B-cell lymphomas (Poggi et al, 2016; Sierra 
et  al,  2017).  All  these  findings  indicate  that  ki67  immunolocalization  is  related  to 
proliferative activity in canine malignant tissue, but to date no data concerning canine 
B-CLL are available.
The  identification  of  novel  markers  for  B-CLL  diagnosis  in  canine  patients  could 
contribute to the better characterization of the malignant clone and help to explain 
the heterogeneity in the clinical behavior of the disease.
Starting from the experience of human medicine the aim of the present study was to 
prospectively investigate the expression of ZAP70, CD25, and KI67 by flow cytometry 
and CD38 mRNA expression by quantitative real-time PCR on canine B-CLL cells. Then,  
we correlated the expression of the markers with some preliminary outcome data. The 
main  purpose  of  the  present  work  was  to  determine  whether  the  markers  are 
expressed or not by leukemic cells and if they could be putative prognostic markers 
with clinical utility. 
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Material and Methods
Eligibility
The present study included newly identified patients affected by B-CLL from 2015 to 
2017 for ki67, ZAP70 and CD25 analysis, and whole blood samples at time of diagnosis 
from patients with B-CLL in the range of time 2010-2016 and stored into RNA later at  
-20 for CD38 transcript analysis in canine cells.
Clinical  data  were  obtained  from  the  medical  records  and  by  phone  calls  to  the 
referring  veterinarians.  Background  information  collected  for  each  dog  included 
signalment, blood count (CBC) at diagnosis, date and cause of death.  All dogs were 
privately owned and blood was collected for diagnostic purposes with the informed 
consent  of  the  owners.  Thus,  a  formal  approval  of  the  Institution  Committee  for 
Animal Care of the authors’ Institutions was not required.
The diagnosis of B-CLL required a persistent lymphocytosis of more than 6 × 10 9/l and 
was based on standard morphologic and immunophenotyping criteria (Workman and 
Vernau,  2003; Adam et al.,  2009; Comazzi  et  al.,  2011).  Routine laboratory studies 
consisted of complete blood count performed with an automated analyzer including 
leukocyte differential and platelet count. Automated differentials were validated by 
microscopic evaluation of blood smears stained with May Grünwald-Giemsa. Anemia 
was defined by PCV<37%. Thrombocytopenia was confirmed if both platelet count was 
<100,000/mL and blood smear showed low platelet estimation and no evidence of 
platelet clumping. 
Exclusion criteria included:
(1) morphology suggestive of immature or blast cells in at least 30% of cells (medium 
to large cell size; round or indented, medium to large nucleus with poorly condensed 
chromatin; the presence of nucleoli or some combination of these),
(2) positivity to CD34,
(3) moderate or severe lymphadenomegaly, splenomegaly, or both with nodal, splenic,  
or both having cytological features compatible with lymphoma. Mild lymphadenopathy 
or splenomegaly
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was not considered an exclusion criterion, except for those cases showing cytological 
features suggestive of specific lymphoma subtypes, and
(4) positive serologic titer for Ehrlichia or Leishmania or any other identifiable cause 
of  lymphocytosis  (eg,  hypoadrenocorticism,  postvaccinal  lymphocytosis,  stress 
lymphocytosis, others).
ZAP70 antibody validation 
Since the use of this antibody in canine species has never been described before, the 
clone used was validated as follow: 
1. reactivity on canine ZAP-70 protein was evaluated by computational analysis 
comparing  the  sequence  of  antigen  polypeptide  provided  by  the  producer 
aligned with the homologous canine sequence. We performed a search of the 
non-redundant protein sequences using the National Center for Biotechnology 
Information  (NCBI)  Basic  Local  Alignment  Search  Tool  (BLAST; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi) using the reference protein sequence;
2. reactivity with canine cells  was  confirmed by Western Blotting using canine 
peripheral blood mononuclear cells as a target; 
3. specific labeling on T circulating lymphocytes from canine blood was confirmed 
using a triple color staining for ZAP-70 and CD5 (T cells) and CD21 (B cells) on 
samples from healthy dogs.
Flow Cytometry
 Standard panel for CLL diagnosis
Flow cytometric immunophenotype was performed as previously reported (first study 
pf the thesis). The B-CLL cases were identified by a homogeneous expansion (>60%) of 
“small”  CD21+  lymphocytes  (Workman  and  Vernau,  2003).  These  cases  were 
considered  “cytology-confirmed”  if  the  report  described  the  majority  of  cells  as 
mature, small, having condensed chromatin.
 Experimental panel
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The experimental  panel was performed on newly diagnosed cases using antibodies 
against ki67, CD25, and ZAP70.
For  ki67  staining,  peripheral  blood  samples  were  labeled  with  a  specific  FITC-
conjugated antibody directed against  Ki67 (Mouse anti-Human, clone MIB-1, DAKO, 
Glostrup, DK) using a fixation/permeabilization method with methanol as previously 
described (Poggi  et al.,  2013). Proliferative activity was expressed as percentage of  
Ki67 positive cells. 
Cell surface expression of CD25 was evaluated by anti-CD25 monoclonal antibody PE-
conjugated (Mouse anti Canine, clone P4A10, eBioscience) and processed as previously 
described  for  surface  antibody  stainings  (Comazzi  et  al.,  2006).  The  analysis  was 
performed on gated lymphocytes and expressed as percentage of CD25 positive cells 
out of lymphocytes population.
For the intracellular  protein ZAP-70, fixation and permeabilization procedures were 
performed using the Leucoperm reagents A and B (Serotec, Oxford, UK) according to 
manufacturer’s  instructions.  ZAP70  antibody  R-PE-conjugated  (Mouse  anti  Human, 
clone SBZAP, Zebra Bioscience, Enschede, Netherlands) was used for the stain. Tubes 
were prepared as follow: negative control (only cells, without antibodies), one tube 
containing CD5-FITC/isotype control-PE/CD21-Alexa 647 (Fluorescence Minus One –
FMO- control),  one tube containing CD5-FITC/ZAP70-PE/CD21-Alexa 647. Afterward, 
the  samples  were  washed  in  phosphate  buffered  saline  (PBS),  resuspended  and 
immediately  acquired  at  the  flow  cytometer.  A  minimum  of  10000  events  was 
acquired and analysis  was performed on gated CD21 positive lymphocytes staining 
positively for ZAP70, using unstained cells. Threshold was defined on CD21 positive 
cells using the FMO tube.
Quantitative real-time RT-PCR for CD38 transcript
Since  cross-reactive  anti-CD38  antibodies  are  currently  not  available  for  dogs,  we 
preliminary investigated this putative marker at RNA level. The transcript analysis was 
performed  on  whole  blood  sample  diluted  in  RNAlater®  (Applied  Biosystems,  Life 
Technologies, Carlsbad, CA) and stored at −20 °C until processing. The total RNA was 
isolated from cell pellets using the RNeasy Mini Kit (Qiagen, Milan, Italy) according to 
the  manufacturer’s  instructions.  To  avoid  genomic  DNA  contamination,  on-column 
DNase digestion with the RNase-Free DNase (Qiagen) set was performed. Total RNA 
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concentration  and  quality  were  measured  with  Qubit  Fluorimeter  (Thermo  Fisher 
Scientific, Waltham, MA USA) using a Qubit RNA HS Assay kit. First-strand cDNA was 
synthesized  from  200  ng  of  total  RNA  using  QuantiTec  Reverse  Transcription  Kit 
(Qiagen) according to the manufacturer’s protocol. The generated cDNA was used as 
template for quantitative real-time RT-PCR (qRT-PCR) in a BioRad CFX Real-Time PCR 
detenction System (BioRad, California, USA) instrument using standard PCR conditions. 
The qRT-PCR reactions consisted of 10 μl of Platinum SYBR Green qPCR SuperMix-UDG 
(Invitrogen, Life Technologies, Carlsbad, CA), 0.3 μl of forward and reverse primers (10 
μM)  and  1  μl  of  diluted  (1–40)  cDNA.  Primers  were  designed  using  Primer3web 
(primer3.ut.ee) based on the corresponding canine genome project gene sequences 
available through Ensembl web site (www.ensembl.org). Canine CD38 was amplified 
using the primer pair 5′- CCT GAT TGT GGT GGG CAT-3′ (forward) and 5′-TCG CAC GAC 
TTG AGT GTA-3′ (reverse) for the amplification of a fragment of 188 base pairs. Canine 
transmembrane BAX inhibitor motif containing 4 (CGI-119) and GAPDH were chosen as 
reference gene for the absence of pathological state dependent differences in mRNA 
expression, as reported by Aricò et al. (2013) and Mortarino et al (2009).
Calibration curves using serial dilution of a control sample revealed PCR efficiency of 
100.1%.  ΔΔCt  method  (Livak  and  Schmittgen,  2001)  was  used  for  the  relative 
quantification of mRNA, ultimately expressed as Relative Expression (RE).
Statistical Analysis
Statistical analysis was performed via SPSS v20.0 for Windows. Statistical significance 
was  set  at  p≤0.05.  To  assess  whether  the  expression  of  the  antibodies  and  the 
transcript could influence survival, we divided cases into low and high expression: an 
arbitrary cutoff was set at the median value calculated of the percentage of positive 
cells for each antibody and the median of relative expression of CD38 mRNA. For ki67 
antibody, the cutoff value of 12.2% used for the discrimination between high grade 
and low-grade lymphomas was also evaluated, based on a previous published paper 
(Poggi  et al.  2013).  Then,  curves were generated by the Kaplan-Meier method and 
compared with the log-rank test. Survival time (ST) was calculated from the date of  
diagnosis of CLL to death. Cases were censored if lost to follow-up, if they died or were 
euthanized because of unrelated causes, or if they were alive at the end of the study. 
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The following factors were investigated using multivariate Cox’s proportional hazard 
regression analysis to assess association with long survival: breed (pure or mixed), sex 
(male or female), age (continuous variable), WBC (continuous variable), presence of 
anemia  (yes  or  not),  presence of  thrombocytopenia (yes  or  not),  total  lymphocyte 
count (continuous variable),  % of B cells (continuous variable), % of ZAP70 positive 
cells (continuous variable), % of CD25 positive cells (continuous variable), % of ki67 
positive cells (continuous variable).
Results
Case description
The  present  analysis  included  peripheral  blood  samples  from  37  newly  identified 
patients affected by B-CLL.
Clinical data were obtained for 27 dogs. Among these, 20 dogs (74%) were of pure 
breed and 7 (26%) were of mixed-breed, with Boxer (n=4) as the most represented 
breed,  followed  by  Maltese  dog  (n=2),  Labrador  Retriever  (n=2)  and  American 
Staffordshire Terrier (n=2). 15 (55.5%) were male (1 neutered) and 12 (45.5%) were 
female (5 spayed).
Overall  median age was 10.5 years (range 3–15 years).  In particular, 10 (37%) dogs 
were <10.5 years old and 17 (63%) were ≥10 .5 years old. 
Hematological  data were obtained for 26 dogs.  Eleven (42.%) dogs were anemic, 7 
(26.9%)  had  thrombocytopenia.  All  dogs  had  lymphocytosis;  the  overall  median 
lymphocyte  count  was  57,32  ×103/L  (range  6.87-885.15  ×103/L),  with  an  overall 
median white blood cell (WBC) count of 69,9 ×103/μL (range 11.3-970.8 ×103/μL). FC 
for CLL diagnosis was carried out for all patients. The percentage of B cells ranged from 
47 to 98 % (median 82%).
Follow up data
Follow up data were available for 17 dogs. Overall median survival was 192 days (dd) 
(range 3-771 dd). Nine of the 17 dogs died of causes related to their leukemia, with a 
median survival of 59 dd (range 3-332). Among the remaining 8 cases, 3 dogs were lost 
to follow up at 187, 563 and 644 dd, 1 dog died of other causes at 206 dd, while 4 dogs 
were alive at data analysis closure at 75, 635, 691 and 771 dd.
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Validation of ZAP70 antibody for flow cytometry
The cross-reactivity of ZAP70 human antibody against  canine cells was investigated 
within  sequence  analysis  of  the  target  epitope.  The  peptide  corresponding  to  the 
amino acids  280-309 of  human ZAP70 was  queried  against  canine  sequences  with 
NCB1 protein BLAST tool.
The antigen recognized by clone SB-ZAP used for the present research showed 86% of 
identity with ZAP70 protein of Canis Lupus Familiaris (Fig.  18).  The substitutions of 
aminoacids don't change the structure of the epitope.
Western blotting analysis on canine PBMC showed a positive band at the expected 
molecular  weight  (70  kD).  Flow  cytometry  on  peripheral  blood  lymphocytes  from 
healthy dogs showed a positivity to ZAP-70 just on CD5 positive cells (T cells) while 
CD21 positive cells (mature B cells) stained negative (Fig. 19).
ZAP70, ki67and CD25 analysis
24 cases were enrolled for the FC experimental panel.
ki67 was performed for 23 cases, CD25 was performed for 21 cases, while ZAP70 was 
performed for 16 cases. The percentage of positive cells ranged from 0.65 to 24.98 % 
(median 4.2 %) for ki67 antibody, from 3.27 to 97,8 % (median 68,4 %) for CD25 and  
from 7.6 to 96.4 % (median 41.6 %) for ZAP70  (Fig. 20-21) (Table 4). 
The prognostic influence of ki67, CD25, and ZAP70 was assessed in our cohort. Follow 
up data  were available  for  just  14 dogs  included in  the experimental  panel.  ST of 
patients with high expression was compared with low expression. An assessment of 
the Kaplan-Meier curves revealed  a highly significant difference between expression 
levels and outcome (p=0.027) for ZAP70: ST was significantly shorter in the group of 
high  expression  of  the  marker.  On  the  contrary,  for  ki67  and  CD25  markers  no 
significance was found, with p=0,287 and p=0,803, respectively, and p=0.07 for ki67 
with  the  12.2%  cutoff  (Fig.21).  Median  ST  were  as  follow:  median  of  ZAP70  low 
expression (n=6): nor reached, ZAP70 high (n=6): 59 dd; CD25 low expression (n=4): 
329 dd, CD25 high expression (n=8): 86 dd; ki67 low expression (n=6): not reached,  
ki67 high expression (n=6): 86 dd; ki67 ≤12.2% (n=19): not reached, ki67 >12.2% (n=4): 
86 dd.
Cox's  multivariate  analysis  revealed  that  none  of  the  variables  considered  was 
significantly associated with survival.
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Figure 18: Allignment of canine ZAP70 peptide to human ZAP70 corresponding the aminoacids  280-309.  
Red: un-conservative change. Green: conservative change. 
Figure 19: flow cytometric analysis on peripheral blood of a healthy dog. A: CD21-alexa 647 VS ZAP70-
pe; circulating B lymphocytes are positive for CD21 and negative for ZAP70 (lower-right quadrant). B:  
CD5-fitc  and ZAP70-pe;  circulating T lymphocytes  are  positive  for  both CD5 and ZAP70 (upper-right 
quadrant). 
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Figure 20: flow cytometric scattergrams representing CD21-alexa 647 VS ZAP70-pe of B-lymphocytes.  
Cells  positive  for  both  CD21 and ZAP70 fall  in  the upper-right  quadrant  of  the scattergrams.  A:  B-
lymphocytes of a healthy dog staining positive for CD21 and negative for ZAP70 . B: a sample of CLL-B  
characterized by low ZAP70 expression. C: a sample of CLL-B characterized by high ZAP70 expression.
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Table 4: percentage of positivity  for ZAP70, CD25 and ki67, and  outcome of dogs enrolled for the FC 
experimental panel
CASE ZAP70 % CD25% ki67 % SURVIVAL OUTCOME
1 34,94 88,14 6,14 644 Lost to follow-up
2 24,7 3,27 1,41 206 Dead (other)
3 35,97 78,76 2,61 771 Alive
4 69,9 46,5 21,4 329 Dead (leukemia)
5 92,03 90,2 4,16 59 Dead (leukemia)
6 96,4 97,8 7,29 49 Dead (leukemia)
7 63,8 88,8 2,84 691 Alive
8 41,6 93,31 12,08 635 Alive
9 41 73,4 12,5 86 Dead (leukemia)
10 41,52 25,6 3,52 na Unavailable
11 66,6 84,2 24,98 4 Dead (leukemia)
12 7,6 12,07 0,65 na Unavailable
13 na na 1,58 187 Lost to follow-up
14 na na 0,6 192 Dead (leukemia)
15 48,2 na 4,96 na Unavailable
16 80,03 46,2 3,2 3 Dead (leukemia)
17 na 3,37 na na Unavailable
18 na 11,2 3 na Unavailable
19 na 64,3 4,2 na Unavailable
20 na 90,2 12,1 na Unavailable
21 na 86,7 8,9 na Unavailable
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22 na 44,3 8,8 na Unavailable
23 19,1 68,4 13,9 na Unavailable
24 22,54 64,89 2,47 75 Alive
CD38 mRNA analysis
24  whole  blood  samples  collected  from  patients  diagnosed  with  B-CLL  at  time  of 
diagnosis and stored into RNA-later at -20 were tested for CD38 mRNA expression in  
canine cells. The real-time analysis revealed that the marker was expressed by cells.  
The distribution of CD38 relative expression in the whole patient cohort was highly 
variable,  ranging between 0.06 and 8.6 (median 2,34) (table  5).  The percentage of 
leukemic cells ranged from 47 to 96 %. Survival time was available for 11 dogs included 
in  the real-time PCR analysis.  The association between patients  with high and low 
expression was also evaluated but no association between the relative expression of 
the protein and survival was found. Median ST for CD38 low expression (n=5) group 
was  332  dd,  while  for  CD38  high  expression  (n=6)  was  86  dd,  p=0,806  (Fig.21). 
Multivariate analysis revealed that none of the clinical and hematological variables was 
significantly associated with survival.
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Fig.ure 21: Kaplan-Meier curves of the markers Zap70, CD25, ki67 and CD38. 
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Table 5: relative expression , expression group and outcome of dogs enrolled  for CD38 analysis.
Case CD38 RE Expression group Survival Outcome
1 7,009823 high Unavailable
2 4,358335 high Unavailable
3 0,829491 low Unavailable
4 4,919763 high 563 Lost
5 0,395959 low 332 Leukemia
6 2,25328 low Unavailable
7 1,71247 low Unavailable
8 0,275799 low Unavailable
9 0,392655 low 27 Leukemia
10 2,341277 low Unavailable
11 4,704521 high Unavailable
12 0,351336 low Unavailable
13 6,783545 high Unavailable
14 0,062443 low 641 Lost
15 3,429273 high Unavailable
16 1,568132 low 771 Alive
17 8,640013 high 59 Leukemia
18 6,975293 high Unavailable
19 0,116931 low 49 Leukemia
20 5,820898 high 691 Alive
21 4,186288 high 635 Alive
22 5,967231 high 86 Leukemia
23 1,234057 low Unavailable
24 4,646609 high 4 Leukemia
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Discussion
In  contrast  with  the  human  counterpart,  B-Chronic  lymphocytic  leukemia  are 
uncommon diseases in dogs in which CD8+ T-CLL is the most diffuse leukemia subtype.  
Recent studies (Brombereck et al., 2016) has described the clinical characteristics and 
breed predisposition of B-CLL in a cohort of 491 dogs but no prognostic information 
was recorded.  In  the present preliminary study,  we prospectively investigated  four 
putative prognostic markers of B-CLL (ZAP-70, Ki67, CD25, and CD38) for their possible 
use via flow cytometry on a prospective clinical study. The choice of these markers was 
based on studies in human CLL, since canine B-CLL shares many features with human 
CLL. In humans, ZAP-70 protein has been considered a predictor of IgVH mutational 
status  in  93%  of  patients.  ZAP-70  expression  and  IgVH  mutation  status  were 
comparable  in  their  ability  to  predict  time  to  treatment  requirement  following 
diagnosis. CLL that is positive for the marker ZAP-70 has an average survival of 8 years 
while CLL that is negative for ZAP-70 has an average survival of more than 25 years 
(Wiestner et al., 2003; Rossi et al., 2010). The evaluation of ZAP-70 in flow cytometry 
assumed a diagnostic role for human CLL in order to predict prognosis, but its use has 
been currently replaced given the availability of feasible and cheap molecular tests to 
directly define mutational status. The molecular testing, in general, can be performed 
using a variety of methods. The methodology used for the test may vary from one 
laboratory to another, however RT-PCR of RNA and sequencing of cDNA of the IGVH 
detection  of  mutation  from  germline  sequence  is  the  preferable  method  (Capello 
2004). IgVH mutation analysis combined with FISH, ZAP-70, and beta-2 microglobulin 
measurement  provide  comprehensive  prognostic  assessment  and  may  be  used  to 
determine the approach to therapy for all CLL patients. 
To our knowledge ZAP-70 expression on lymphoid cells has not been yet described in  
dogs but ZAP-70 has been evaluated by our research group at mRNA level showing a 
high expression in T lymphocytes and T-CLL neoplastic cells (Mortarino et al., 2009). In 
canine B-CLL a variable expression of ZAP-70 mRNA was found but its prognostic role 
has not been elucidated yet. In the present research, we evaluated ZAP-70 protein 
expression on B neoplastic cells from canine B-CLL using a monoclonal antibody (clone 
SB ZAP) designed for the human protein. The cross-reactivity of the antibody was first 
evaluated comparing “in silico” canine and human sequences via Blast tool then by 
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Western Blotting on peripheral  blood mononuclear cells.  In addition, reactivity was 
evaluated via FC on normal lymphocytes from healthy dogs, confirming that ZAP-70 is 
expressed  in  T-cell  subtypes  but  not  in  normal  circulating  B-cells.  In  contrast, 
neoplastic B-CLL cells expressed variable positivities to ZAP-70 (Table 4). Preliminary 
assessment of the possible prognostic value of ZAP-70, using an arbitrary cut-off set at 
the median percentage value of all B-CLL cases (41,6%), showed that cases with high 
expression of ZAP-70 are statistically correlated to a shorter survival, similarly to what  
reported in humans. Results open interesting perspectives on the possible use of this 
marker in a clinical setup to predict prognosis, although our data need to be validated 
on a larger cohort of dogs with an adequate follow-up and a consistent therapy in  
order to define the best cutoff value to discriminate between long and short survivor 
dogs. In addition, more studies will be necessary to define if, similarly to humans, the 
positivity  to  ZAP-70  is  related  to  IgVH  mutational  status  that  has  been  recently 
evaluated in a recent paper in dogs showing a breed predilection pattern (Rout et al.,  
2018).
Ki67 is a non-histone nuclear protein expressed in all active phases of the cell cycle and 
virtually absent in resting cells. Its use as a diagnostic and prognostic marker is well  
documented  in  various  human  malignancies  and  recently  our  research  group 
developed a flow cytometric test to evaluate Ki67 in lymphoma cells showing a good 
correlation with tumor grading by using a cutoff value of 12,2% (Poggi et al, 2015). In  
the present paper we evaluated the percentage of Ki67 positive cells using both an 
arbitrary cutoff set at the median percentage of B-CLL cells (4,2 %) and the cutoff value 
suggested for lymphoma by Poggi et al. In both the cases no statistical association with 
survival  time was found but the lower percentage value rendered a lower p value 
suggesting that this marker should be evaluated on a wider cohort of dogs to definitely 
rule out its possible use as a prognostic index or, as an alternative, to define the best 
cutoff value to be used in a clinical setup.
CD25  is  an  activation  marker  in  lymphocytes  that  has  been  described  as  variably 
expressed by canine B-CLL and other lymphoid malignancies, with a predilection on 
some specific breeds. The rationale to test this antigen on canine B-CLL is that, since 
CD25 has been reported to be expressed in B memory cells (Amu et al, 2007), it could 
be related to a more mature development pattern that could be linked to a different 
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outcome. However, results from this preliminary study did not show any association 
between CD25 expression and ST, neither in terms of statistical analysis nor as a trend, 
thus suggesting that it is not a promising marker for predicting prognosis.
CD38 is a cell surface glycoprotein acting as an enzyme and a receptor for CD31.
In humans with CLL, the expression of CD38 is correlated to the one of CD49d, marking 
a CLL subset with very poor prognosis  (Zucchetto et al,  2012).  Similarly to ZAP-70, 
CD38 immunoreactivity has been also considered a surrogate of high-risk subtype of 
CLL  and  of  un-mutated  IgGVH.  Since  to  date,  neither  specific  or  cross-reactive 
antibodies are available for canine CD38 we decided to use a molecular approach to 
preliminary investigate at RNA level if this molecule could be associated to a different 
outcome  in  dogs  with  B-CLL.  Unfortunately,  our  preliminary  results  seems  to 
discourage  the  use  of  such  a  target  for  prognostic  purposes  in  dogs  since  no 
correlation was found among survival and CD38 mRNA. The limit of such an approach 
is that we evaluated mRNA for CD38 on all leukocytes population and not on sorted 
neoplastic cells and this could have biased results since gene expression could have 
been influenced by other subtypes than neoplastic cells. However, no correlation was 
found among CD38 mRNA relative expression and purity of neoplastic cells determined 
via FC, thus we consider CD38 as a less promising prognostic marker for canine B-CLL, 
also in light of the lack of a specific antibody for FC.
One of  the major  pitfalls  of  the present  study  is  the low number  of  cases  with a  
complete follow- up. However, to date, very few papers investigating the outcome of 
B-CLL are available (Comazzi et al., 2011) and the long survival of such diseases make 
difficult to reach the end point of new prospective studies. An increase of caseload 
with an adequate follow-up is necessary to confirm our preliminary results.
The second pitfall to be considered is related to therapy which is not consistent among 
cases  enrolled.  Therapies  were  highly  variable  among  cases  and  were  left  to  the 
clinician’s  and  the  owner’s  choice,  varying  from  no  therapy,  to  corticosteroids,  to 
chlorambucil and this treatment may be variable also in the same patients during the 
time. In addition, a previous work (Comazzi et al., 2011) demonstrated that therapies 
have minimal or no effect on overall survival of dogs with CLL and that the choice for 
different protocols is generally based on the clinical status of the patient and aimed to 
improve the quality of life and to reduce complications.
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Again an increase of caseload will be advisable to confirm these results in dogs treated 
in a consistent way. 
The results  of  the present study suggest  that  ZAP-70 and Ki67 are  likely the most 
promising target molecules to be investigated via FC to predict prognosis of B-CLL.  
Further prospective studies on a larger cohort of dogs, treated with the same protocol 
and with a long follow-up (in light of the indolent behavior of CLL) are needed not only  
to confirm our results but also to define the best cutoff values useful in a clinical setup 
to split population with different outcomes.
The results of the present study will be object of a specific paper to be submitted to  
peer review international journals.
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4. Conclusions
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Results  achieved  within  the  present  project  provide  useful  information  for  the 
definition of some specific tumor entities, and support the use of FC for the diagnosis 
of lymphoproliferative neoplasms.
In particular, from the first study emerge that flow cytometry performed on canine LN 
FNA specimens is a suitable diagnostic tool to confirm lymphoma, regardless of animal 
characteristics.  Veterinarians  should  make  any  possible  effort  to  obtain  a  highly 
cellular sample.  
Regarding TZL, we can confirm that it is an indolent lymphoma characterized by a long 
survival, despite the V stage of the disease at presentation. We can also state that the 
absence of CD45 protein is likely due to the absence of gene transcription, providing a  
new tile for the comprehension of the pathogenesis of this tumor. 
The issue of nMZL, disclosed that dogs may present at an advanced stage of disease 
with an overall poor prognosis, providing useful information for better understanding 
the behavior of this entity,  usually classify as indolent,  and opening a discussion of 
clinical interest about therapeutic approach.
Finally, the study on B-CLL encourages further investigations for the use of ZAP70 as 
novel marker for B-CLL stratification. 
All the studies taken together underline, another time, how the use of FC could be an  
important  resource in  veterinary  oncohematology,  for  both diagnosis  and practical 
approach to the disease.
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